0001683168-22-007290.txt : 20221107 0001683168-22-007290.hdr.sgml : 20221107 20221107073025 ACCESSION NUMBER: 0001683168-22-007290 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 45 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221107 DATE AS OF CHANGE: 20221107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sunshine Biopharma, Inc CENTRAL INDEX KEY: 0001402328 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 205566275 STATE OF INCORPORATION: CO FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-41282 FILM NUMBER: 221363724 BUSINESS ADDRESS: STREET 1: 6500 TRANS-CANADA HIGHWAY STREET 2: 4TH FLOOR CITY: POINTE-CLAIRE STATE: A8 ZIP: H9R 0A5 BUSINESS PHONE: 514-426-6161 MAIL ADDRESS: STREET 1: 6500 TRANS-CANADA HIGHWAY STREET 2: 4TH FLOOR CITY: POINTE-CLAIRE STATE: A8 ZIP: H9R 0A5 FORMER COMPANY: FORMER CONFORMED NAME: Mountain West Business Solutions, Inc DATE OF NAME CHANGE: 20071030 FORMER COMPANY: FORMER CONFORMED NAME: mountain west business solutions,inc DATE OF NAME CHANGE: 20070607 10-Q 1 sunshine_i10q-093022.htm FORM 10-Q
0001402328 false --12-31 2022 Q3 0001402328 2022-01-01 2022-09-30 0001402328 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001402328 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001402328 2022-11-07 0001402328 2022-09-30 0001402328 2021-12-31 0001402328 us-gaap:SeriesBPreferredStockMember 2022-09-30 0001402328 us-gaap:SeriesBPreferredStockMember 2021-12-31 0001402328 2022-07-01 2022-09-30 0001402328 2021-07-01 2021-09-30 0001402328 2021-01-01 2021-09-30 0001402328 2020-12-31 0001402328 2021-09-30 0001402328 us-gaap:CommonStockMember 2022-06-30 0001402328 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001402328 us-gaap:PreferredStockMember 2022-06-30 0001402328 us-gaap:ComprehensiveIncomeMember 2022-06-30 0001402328 us-gaap:RetainedEarningsMember 2022-06-30 0001402328 2022-06-30 0001402328 us-gaap:CommonStockMember 2021-12-31 0001402328 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001402328 us-gaap:PreferredStockMember 2021-12-31 0001402328 us-gaap:ComprehensiveIncomeMember 2021-12-31 0001402328 us-gaap:RetainedEarningsMember 2021-12-31 0001402328 us-gaap:CommonStockMember 2021-06-30 0001402328 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001402328 us-gaap:PreferredStockMember 2021-06-30 0001402328 us-gaap:ComprehensiveIncomeMember 2021-06-30 0001402328 us-gaap:RetainedEarningsMember 2021-06-30 0001402328 2021-06-30 0001402328 us-gaap:CommonStockMember 2020-12-31 0001402328 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001402328 us-gaap:PreferredStockMember 2020-12-31 0001402328 us-gaap:ComprehensiveIncomeMember 2020-12-31 0001402328 us-gaap:RetainedEarningsMember 2020-12-31 0001402328 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001402328 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001402328 us-gaap:PreferredStockMember 2022-07-01 2022-09-30 0001402328 us-gaap:ComprehensiveIncomeMember 2022-07-01 2022-09-30 0001402328 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001402328 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001402328 us-gaap:PreferredStockMember 2022-01-01 2022-09-30 0001402328 us-gaap:ComprehensiveIncomeMember 2022-01-01 2022-09-30 0001402328 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001402328 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001402328 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001402328 us-gaap:PreferredStockMember 2021-07-01 2021-09-30 0001402328 us-gaap:ComprehensiveIncomeMember 2021-07-01 2021-09-30 0001402328 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001402328 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001402328 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0001402328 us-gaap:PreferredStockMember 2021-01-01 2021-09-30 0001402328 us-gaap:ComprehensiveIncomeMember 2021-01-01 2021-09-30 0001402328 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0001402328 us-gaap:CommonStockMember 2022-09-30 0001402328 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001402328 us-gaap:PreferredStockMember 2022-09-30 0001402328 us-gaap:ComprehensiveIncomeMember 2022-09-30 0001402328 us-gaap:RetainedEarningsMember 2022-09-30 0001402328 us-gaap:CommonStockMember 2021-09-30 0001402328 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001402328 us-gaap:PreferredStockMember 2021-09-30 0001402328 us-gaap:ComprehensiveIncomeMember 2021-09-30 0001402328 us-gaap:RetainedEarningsMember 2021-09-30 0001402328 SBFM:AegisOfferingMember 2022-02-16 2022-02-17 0001402328 SBFM:AegisOfferingMember us-gaap:CommonStockMember 2022-02-16 2022-02-17 0001402328 SBFM:AegisOfferingMember SBFM:TradeableWarrantsMember 2022-02-16 2022-02-17 0001402328 2022-02-21 2022-02-22 0001402328 us-gaap:PrivatePlacementMember us-gaap:CommonStockMember 2022-03-13 2022-03-14 0001402328 us-gaap:PrivatePlacementMember SBFM:InvestorWarrants1Member 2022-03-13 2022-03-14 0001402328 us-gaap:PrivatePlacementMember SBFM:PreFundedWarrantsMember 2022-03-13 2022-03-14 0001402328 us-gaap:PrivatePlacementMember 2022-03-13 2022-03-14 0001402328 us-gaap:PrivatePlacementMember 2022-04-01 2022-04-28 0001402328 us-gaap:PrivatePlacementMember us-gaap:CommonStockMember 2022-04-01 2022-04-28 0001402328 us-gaap:PrivatePlacementMember SBFM:InvestorWarrants2Member 2022-04-01 2022-04-28 0001402328 us-gaap:PrivatePlacementMember SBFM:PreFundedWarrants1Member 2022-04-01 2022-04-28 0001402328 us-gaap:WarrantMember 2022-04-28 0001402328 SBFM:FirstReverseStockSplitMember 2019-01-31 2019-02-01 0001402328 SBFM:SecondReverseStockSplitMember 2020-04-05 2020-04-06 0001402328 SBFM:ThirdReverseStockSplitMember 2022-02-08 2022-02-09 0001402328 SBFM:NotePayable20211Member 2021-04-20 0001402328 SBFM:NotePayable20211Member 2021-04-19 2021-04-20 0001402328 SBFM:NotePayable20211Member 2022-02-16 2022-02-17 0001402328 SBFM:NotePayable20212Member 2021-07-06 0001402328 SBFM:NotePayable20212Member 2021-07-05 2021-07-06 0001402328 SBFM:NotePayable20212Member 2022-02-16 2022-02-17 0001402328 SBFM:NotePayable20213Member 2021-08-18 0001402328 SBFM:NotePayable20213Member 2021-08-17 2021-08-18 0001402328 SBFM:NotePayable20213Member 2022-02-16 2022-02-17 0001402328 2022-02-01 2022-02-17 0001402328 us-gaap:SeriesBPreferredStockMember 2022-02-01 2022-02-22 0001402328 us-gaap:SeriesBPreferredStockMember 2022-02-22 0001402328 us-gaap:PrivatePlacementMember SBFM:InvestorWarrantsMember 2022-03-13 2022-03-14 0001402328 SBFM:PreFundedWarrantsMember 2022-01-01 2022-09-30 0001402328 SBFM:PreFundedWarrantsMember 2022-09-30 0001402328 SBFM:TradeableWarrantsMember 2022-01-01 2022-09-30 0001402328 SBFM:TradeableWarrantsMember 2022-09-30 0001402328 SBFM:InvestorWarrantsMember 2022-01-01 2022-09-30 0001402328 SBFM:InvestorWarrantsMember 2022-09-30 0001402328 SBFM:AprilWarrantsMember 2022-01-01 2022-09-30 0001402328 SBFM:AprilWarrantsMember 2022-09-30 0001402328 SBFM:InvestorWarrantsAndAprilWarrantsMember 2022-01-01 2022-09-30 0001402328 SBFM:AegisOfferingMember SBFM:TradeableWarrantsMember 2022-02-01 2022-02-28 0001402328 us-gaap:PrivatePlacementMember SBFM:InvestorWarrantsMember 2022-04-01 2022-04-22 0001402328 us-gaap:PrivatePlacementMember SBFM:AprilWarrantsMember 2022-04-01 2022-04-22 0001402328 SBFM:AdvanomicsCorporationMember 2022-01-01 2022-09-30 0001402328 SBFM:OfficersAndDirectorsMember 2021-07-01 2021-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

Form 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended: September 30, 2022

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ____________ to ______________

 

Commission File Number: 001-41282

 

SUNSHINE BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

 

Colorado   20-5566275
(State of other jurisdiction of incorporation)   (IRS Employer ID No.)

 

6500 Trans-Canada Highway

4th Floor

Pointe-Claire, Quebec, Canada H9R 0A5

(Address of principal executive offices)

 

(514) 426-6161

(Issuer’s Telephone Number)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class Trading Symbol Name of Each Exchange on Which Registered

Common Stock

Common Stock Purchase Warrants

SBFM

SBFMW

The NASDAQ Stock Market LLC

The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes ☒   No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one)

 

  Large accelerated filer  ☐ Accelerated filer  ☐
  Non-accelerated filer  ☒ Smaller reporting company  ☒
    Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes  ☒ No

 

The number of shares of the registrant’s common stock, par value $0.001, issued and outstanding as of November 7, 2022, was 22,585,632 shares.

 

 

 

   

 

 

TABLE OF CONTENTS

 

    Page No
     
  PART I. FINANCIAL INFORMATION  
     
Item 1. Financial Statements 2
  Condensed Consolidated Balance Sheets as of September 30, 2022 (Unaudited) and December 31, 2021 2
  Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2022 and 2021 (Unaudited) 3
  Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2022 and 2021 (Unaudited) 4
  Condensed Consolidated Statement of Shareholders' Equity (Unaudited) 5
  Notes to Unaudited Condensed Consolidated Financial Statements 6
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 12
Item 3. Quantitative and Qualitative Disclosures About Market Risk 18
Item 4. Controls and Procedures 18

 

  PART II. OTHER INFORMATION  
   
Item 1. Legal Proceedings 19
Item 1A. Risk Factors 19
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 19
Item 3. Defaults Upon Senior Securities 19
Item 4. Mine Safety Disclosures 19
Item 5. Other Information 19
Item 6. Exhibits 19
  Signatures 20

 

 

 

 2 

 

  

PART I.  FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

Sunshine Biopharma, Inc.

Condensed Consolidated Balance Sheets

 

           
   September 30,   December 31, 
   2022   2021 
   Unaudited     
ASSETS        
         
Current Assets:          
Cash and cash equivalents  $40,555,931   $2,045,167 
Accounts receivable   22    7,798 
Inventory   269,641    105,650 
Prepaid expenses   27,390    29,625 
Deposits   7,590    7,590 
Total Current Assets   40,860,574    2,195,830 
           
Equipment, net   3,770    7,061 
           
TOTAL ASSETS  $40,864,344   $2,202,891 
           
LIABILITIES AND SHAREHOLDERS' EQUITY          
           
Current Liabilities:          
Accounts payable and accrued expenses  $480,209   $42,942 
Interest payable   –    48,287 
Total Current Liabilities   480,209    91,229 
           
Long-term portion of notes payable   –    1,900,000 
           
TOTAL LIABILITIES   480,209    1,991,229 
           
SHAREHOLDERS' EQUITY          
           
Preferred Stock, Series B $0.10 par value per share; 1,000,000 shares authorized; 10,000 and 1,000,000 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively   1,000    100,000 
Common Stock, $0.001 par value per share; 3,000,000,000 shares authorized; 18,885,632 and 2,591,240 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively   18,886    2,591 
Capital paid in excess of par value   76,331,451    32,787,384 
Accumulated comprehensive (loss)   (79,903)   (23,139)
Accumulated (deficit)   (35,887,299)   (32,655,174)
           
TOTAL SHAREHOLDERS' EQUITY   40,384,135    211,662 
           
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY  $40,864,344   $2,202,891 

 

See Accompanying Notes.

 

 

 

 3 

 

 

Sunshine Biopharma, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

 

                     
   3 Months Ended   9 Months Ended 
   September 30,   September 30,   September 30,   September 30, 
   2022   2021   2022   2021 
         .         . 
Revenues  $132,808   $50,376   $405,760   $143,308 
Cost of sales   65,783    19,506    200,311    56,541 
Gross profit   67,025    30,870    205,449    86,767 
                     
General and Administrative Expenses:                    
Accounting   122,913    35,000    237,773    96,200 
Advertising and Marketing   217,666    –    400,386    – 
Consulting   162,852    20,598    270,033    53,168 
Legal   142,883    56,923    388,238    159,074 
Office   76,818    58,959    449,730    159,762 
Officer and director remuneration   695,000    130,000    1,305,000    1,173,927 
Patent fees   3,584    1    15,148    14,571 
R&D   362,500    222,465    770,095    581,011 
Depreciation   789    3,183    6,186    9,557 
Total General and Administrative Expenses   1,785,005    527,129    3,842,589    2,247,270 
                     
(Loss) from operations   (1,717,980)   (496,259)   (3,637,140)   (2,160,503)
                     
Other Income (Expense):                    
Foreign exchange gain   25    37    45    31 
Interest income   260,938    –    406,984    – 
Interest expense   (2)   (46,849)   (12,866)   (292,188)
Debt forgiveness   –    7,688    10,852    58,940 
Loss on debt conversions   –    (3,504,000)   –    (10,709,843)
Total Other Income (Expense)   260,961    (3,543,124)   405,015    (10,943,060)
                     
Net (loss) before income taxes   (1,457,019)   (4,039,383)   (3,232,125)   (13,103,563)
Provision for income taxes   –    –    –    – 
Net (Loss)  $(1,457,019)  $(4,039,383)  $(3,232,125)  $(13,103,563)
                     
(Loss) from foreign exchange translation   (45,126)   (5,839)   (56,764)   (14,604)
Comprehensive (Loss)  $(1,502,145)  $(4,045,222)  $(3,288,889)  $(13,118,167)
                     
Basic (loss) per common share  $(0.08)  $(1.59)  $(0.26)  $(5.73)
                     
Weighted Average Common Shares Outstanding (Basic)   18,885,632    2,542,640    12,789,733    2,287,682 

 

See Accompanying Notes.

 

 

 

 4 

 

 

Sunshine Biopharma, Inc.

Condensed Consolidated Statements of Cash Flows (Unaudited)

 

           
   9 Months Ended 
   September 30,   September 30, 
   2022   2021 
         
Cash Flows From Operating Activities:          
Net (Loss)  $(3,232,125)  $(13,103,563)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   6,186    9,557 
Foreign exchange (gain) loss   45    (31)
Stock issued for services   –    918,000 
Stock issued for payment interest   –    38,201 
Loss on debt conversion   –    10,709,843 
Debt forgiveness   (10,852)   (58,940)
Decrease in accounts receivable   7,776    787 
(Increase) in inventory   (163,991)   (47,539)
(Increase) decrease in prepaid expenses   2,235    (22,268)
Increase (decrease) in Accounts Payable & accrued expenses   437,267    (13,778)
Increase (decrease) in interest payable   (48,287)   52,716 
Net Cash Flows (Used) in Operations   (3,001,746)   (1,517,015)
           
Cash Flows From Financing Activities:          
Proceeds public offerings, net   43,560,363    3,318,500 
Purchase of preferred shares   (99,000)   61,500 
Payments of notes payable   (1,900,000)   (451,661)
Net Cash Flows Provided by Financing Activities   41,561,363    2,928,339 
           
Cash and Cash Equivalents at Beginning of Period   2,045,167    989,888 
Net increase in cash and cash equivalents   38,559,617    1,411,324 
Effect of exchange rate changes on cash   (105,617)   – 
Foreign currency translation adjustment   56,764    (14,604)
Cash and Cash Equivalents at End of Period  $40,555,931   $2,386,608 
           
Supplementary Disclosure of Cash Flow Information:          
Stock issued for note conversions including interest  $–   $11,981,072 
Cash paid for interest  $61,151   $155,081 
Cash paid for income taxes  $–   $– 

 

See Accompanying Notes.

 

 

 

 5 

 

 

Sunshine Biopharma, Inc.

Condensed Consolidated Statement of Shareholders' Equity (Unaudited)

 

                                         
   Number Of Common        Capital Paid in Excess   Number Of Preferred                 
   Shares   Common   of Par   Shares   Preferred   Comprehensive   Accumulated     
   Issued   Stock   Value   Issued   Stock   Income   Deficit   Total 
Three Month Period                                
Balance at June 30, 2022   18,885,632   $18,886   $76,331,451    10,000   $1,000   $(34,777)  $(34,430,280)  $41,886,280 
                                         
Net (loss)   –    –    –    –    –    (45,126)   (1,457,019)   (1,502,145)
                                         
Balance at September 30, 2022   18,885,632   $18,886   $76,331,451    10,000    1,000   $(79,903)  $(35,887,299)   40,384,135 
                                         
Nine Month Period                                        
Balance December 31, 2021   2,595,620   $2,596   $32,787,379    1,000,000   $100,000   $(23,139)  $(32,655,174)  $211,662 
                                         
Common stock and pre-funded warrants issued in an underwritten public and private offerings, net of issuance costs   6,656,526    6,657    30,360,528    –    –    –    –    30,367,185 
                                         
Exercise of warrants   9,633,486    9,633    13,183,544    –    –    –    –    13,193,177 
                                         
Preferred stock purchased from related party   –    –    –    (990,000)   (99,000)   –    –    (99,000)
                                         
Net (loss)   –    –    –    –    –    (56,764)   (3,232,125)   (3,288,889)
                                         
Balance at September 30, 2022   18,885,632   $18,886   $76,331,451    10,000   $1,000   $(79,903)  $(35,887,299)  $40,384,135 
                                         
Three Month Period                                        
Balance June 30, 2021   2,430,466   $2,430   $28,319,403    1,000,000   $100,000   $(11,636)  $(29,282,907)  $(872,710)
                                         
Common stock issued for the reduction of notes payable and payment of interest   120,000    120    3,743,880    –    –    –    –    3,744,000 
                                         
Net (loss)   –    –    –    –    –    (5,839)   (4,039,383)   (4,045,222)
                                         
Balance at September 30, 2021   2,550,466   $2,550   $32,063,283    1,000,000   $100,000   $(17,475)  $(33,322,290)  $(1,173,932)
                                         
Nine Month Period                                        
Balance December 31, 2020   1,732,096   $1,732   $19,165,029    1,000,000   $100,000   $(2,871)  $(20,218,727)  $(954,837)
                                         
Common stock issued for the reduction of note payable and payment of interest   518,370    518    11,980,554    –    –    –    –    11,981,072 
                                         
Common stock issued for services   300,000    300    917,700    –    –    –    –    918,000 
                                         
Net (loss)   –    –    –    –    –    (14,604)   (13,103,563)   (13,118,167)
                                         
Balance at September 30, 2021 (unaudited)   2,550,466   $2,550   $32,063,283    1,000,000   $100,000   $(17,475)  $(33,322,290)  $(1,173,932)

 

See Accompanying Notes.

 

 

 

 6 

 

 

Sunshine Biopharma, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

For the Three and Nine Month Interim Periods Ended September 30, 2022 and 2021

 

Note 1 – Nature of Business

 

Sunshine Biopharma, Inc. (the “Company”) was originally incorporated under the name Mountain West Business Solutions, Inc. on August 31, 2006, in the State of Colorado. Until October 2009, the Company was operating as a business consultancy firm.

 

Effective October 15, 2009, the Company acquired Sunshine Biopharma, Inc. in a transaction classified as a reverse acquisition. Sunshine Biopharma, Inc. held an exclusive license to a new anticancer drug bearing the laboratory name, Adva-27a (the “License Agreement”). Upon completion of the reverse acquisition transaction, the Company changed its name to Sunshine Biopharma, Inc. and began operating as a pharmaceutical company focusing on the development of the licensed Adva-27a anticancer drug.

 

In December 2015, the Company acquired all issued (US Patent Number 8,236,935, and 10,272,065) and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029 for the Adva-27a anticancer compound from Advanomics Corporation, a related party, and terminated the License Agreement. In 2016, the remaining value of these patents was impaired. The Company is however continuing development of the Adva-27a anticancer drug covered by these patents.

 

In December 2018, the Company launched a Science-Based Nutritional Supplements product, Essential 9™, an over-the-counter capsule comprised of the nine (9) essential amino acids that the human body cannot make. Essential 9™ has been authorized for marketing by Health Canada under NPN 80089663.

 

On May 22, 2020, the Company filed a provisional patent application in the United States for a new treatment for Coronavirus infections. The Company’s patent application covers composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease, Mpro, an enzyme that is essential for viral replication. The patent application has a priority date of May 22, 2020. On April 30, 2021, the Company filed a PCT application containing new research results and extending coverage to include the Coronavirus Papain-Like protease, PLpro. The priority date of May 22, 2020 has been maintained in the newly filed PCT application. The Company’s lead Anti-Coronavirus compound arising from these patents bears the laboratory name SBFM-PL4.

 

On January 26, 2021, the Company received a Notice of Allowances from the Canadian Intellectual Property Office for a new patent application covering Adva-27a. The newly issued patent contains new subject matter and extends the proprietary protection of Adva-27a in Canada until 2033.

 

On March 9, 2021, the Company received a Notice of Allowance from the European Patent Office for a new patent application covering Adva-27a. The newly issued patent contains new subject matter and extends the proprietary protection of Adva-27a in Europe until 2033. The equivalent patent in the United States was issued in 2019 (US Patent Number 10,272,065).

 

On February 15, 2022, the Company entered into an underwriting agreement with Aegis Capital Corp. as underwriter, for the issuance and sale in an underwritten public offering of 1,882,353 Units, each consisting of one share of common stock and two warrants (“Tradeable Warrants”) to purchase shares of common stock at a public offering price of $4.25 per Unit for total gross proceeds of $8,000,000 (“Public Offering”). On February 17, 2022, the Public Offering closed and the Company received net proceeds of $6,833,071. Pursuant to the Public Offering, the Company issued and sold an aggregate of 1,882,353 shares of common stock and 4,102,200 Tradeable Warrants (including 337,494 Tradeable Warrants purchased at $0.01 per warrant resulting from partial exercise of the overallotment option granted to the underwriter). In connection with these transactions, the Company’s shares of common stock and Tradeable Warrants began trading on Nasdaq under the symbol “SBFM” for the common stock and “SBFMW” for the Tradeable Warrants.

 

 

 

 7 

 

 

On February 18, 2022, the Company entered into a research agreement (the “SRA”) with the University of Arizona for the purposes of conducting research focused on determining the in vivo safety, pharmacokinetics, and dose selection properties of three University of Arizona owned PLpro inhibitors, to be followed by efficacy testing in mice infected with SARS-CoV-2 (the “Research Project”). Under the SRA, the University of Arizona granted the Company a first option to negotiate a commercial, royalty-bearing license for all intellectual property developed by University of Arizona personnel under the Research Project. In addition, the Company and the University of Arizona entered into an Option Agreement whereby the Company was granted a first option to negotiate a royalty-bearing commercial license for the underlying technology of the Research Project. Intending to move forward with the technology, the Company submitted a Notice of Option Exercise to the University of Arizona on September 13, 2022.

 

On February 22, 2022, the Company redeemed 990,000 shares of the Series B Preferred Stock from the CEO of the Company at a redemption price equal to the stated value of $0.10 per share.

 

On March 14, 2022, the Company completed a private placement wherein the Company sold (i) 2,301,353 shares of its common stock together with warrants (the “Investor Warrants”) to purchase up to 2,301,353 shares of common stock, and (ii) 1,302,251 pre-funded warrants (“Pre-Funded Warrants”) with each Pre-Funded Warrant exercisable for one share of common stock, together with Investor Warrants to purchase up to 1,302,251 shares of common stock. Each share of common stock and accompanying Investor Warrant were sold together at a combined offering price of $2.22, and each Pre-Funded Warrant and accompanying Investor Warrant were sold together at a combined offering price of $2.219. The Company received approximately $8 million in gross proceeds, and $6,781,199 in net proceeds in this offering.

 

On April 28, 2022, the Company completed another private placement and received net proceeds of $16,752,915. In connection with this private placement, the Company issued (i) 2,472,820 shares of its common stock together with warrants (“April Warrants”) to purchase up to 4,945,640 shares of common stock, and (ii) 2,390,025 pre-funded warrants (“Pre-Funded Warrants”) with each Pre-Funded Warrant exercisable for one share of common stock, together with April Warrants to purchase up to 4,780,050 shares of common stock. Each share of common stock and accompanying two April Warrants were sold together at a combined offering price of $4.01, and each Pre-Funded Warrant and accompanying two April Warrants were sold together at a combined offering price of $4.01, and each Pre-Funded Warrant and accompanying two April Warrants were sold together at a combined offering price of $4.009. The Pre-Funded Warrants were immediately exercisable, at a nominal exercise price of $0.001, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The April Warrants have an exercise price of $3.76 per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance and will expire five years from the date of issuance.

 

On October 20, 2022, the Company acquired Nora Pharma Inc. (“Nora Pharma”), a Canadian generic pharmaceuticals company. Based in the greater Montreal area, Nora Pharma has 36 employees and operates in a 15,000 square foot facility certified by Health Canada. Nora Pharma currently offers over 50 pharmaceutical products, including generic prescription drugs, over-the-counter products and biosimilars. Nora Pharma sales were $10.7 million (USD) during its fiscal year ended June 30, 2022.

 

Note 2 – Basis of Presentation

 

The unaudited financial statements of the Company for the nine month periods ended September 30, 2022 and 2021 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Regulation S-X. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. However, such information reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year. The balance sheet information as of December 31, 2021 was derived from the audited financial statements included in the Company's financial statements as of and for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 21, 2022. These financial statements should be read in conjunction with that report.

 

Note 3 – Impact of Coronavirus (COVID-19) Pandemic

 

In March 2020, the World Health Organization declared Coronavirus and its associated disease, COVID-19, a global pandemic. Conditions surrounding the Coronavirus outbreak have been and are continuing to evolve rapidly. Government authorities in the U.S. and around the world have implemented emergency measures to mitigate the spread of the virus. The outbreak and related mitigation measures have had and will continue to have a material adverse impact on the world economies and the Company's business activities. It is not possible for the Company to predict the duration or magnitude of the adverse conditions of the outbreak and their effects on the Company’s business or ability to raise funds. No adjustments have been made to the amounts reported in the Company's financial statements as a result of this matter.

 

 

 

 8 

 

 

Note 4 – Reverse Stock Splits

 

Effective February 1, 2019, the Company completed a 20 to 1 reverse split of its common stock (the “First Reverse Stock Split”).

 

Effective April 6, 2020, the Company completed another 20 to 1 reverse split of its common stock (the “Second Reverse Stock Split”).

 

Effective February 9, 2022, the Company completed a 1 for 200 reverse split of its common stock (the “Third Reverse Stock Split”).

 

The Company's financial statements reflect the First, Second, and Third Reverse Stock Split on a retroactive basis for all periods presented and for all references to common stock, unless specifically stated otherwise.

 

Note 5 – Notes Payable

 

As of September 30, 2022 and December 31, 2021, the Company had $0 and $1,900,000, respectively in notes payable outstanding. At September 30, 2022 and December 31, 2021, total accrued interest on Notes Payable was $0 and $48,287, respectively.

 

The Company’s Notes Payable at December 31, 2021 consisted of the following:

 

On April 20, 2021, the Company received monies in exchange for a Note Payable having a Face Value of $500,000 with interest accruing at 5% due April 20, 2023. The Note was convertible after 180 days from issuance into common stock at a price equal to $0.30 per share. On February 17, 2022, the Company paid off the entire principal balance of this Note, together with accrued interest of $20,753 by making cash payment of $520,753.

 

On July 6, 2021, the Company received monies in exchange for a Note Payable having a Face Value of $900,000 with interest accruing at 5%, due July 6, 2023. The Note was convertible after 180 days from issuance into common stock at a price equal to $0.30 per share. On February 17, 2022, the Company paid off the entire principal balance of this Note, together with accrued interest of $27,863 by making cash payment of $927,863.

 

On August 18, 2021, the Company received monies in exchange for a Note Payable having a Face Value of $500,000 with interest accruing at 5%, due August 18, 2023. The Note was convertible after 180 days from issuance into common stock at a price equal to $0.30 per share. On February 17, 2022, the Company paid off the entire principal balance of this Note, together with accrued of $12,534 by making cash payment of $512,534.

 

Note 6 – Shareholders’ Equity

 

On February 17, 2022, the Company’s Public Offering closed and the Company received net proceeds of $6,833,071 from the offering. Pursuant to the Public Offering, the Company issued and sold an aggregate of 1,882,353 shares of common stock and 4,102,200 Tradeable Warrants (including 337,494 Tradeable Warrants resulting from partial exercise of the overallotment option granted to the underwriter).

 

On February 22, 2022, the Company redeemed 990,000 shares of Series B Preferred Stock from the CEO of the Company at a redemption price equal to the stated value of $0.10 per share.

 

On March 14, 2022, the Company completed a private placement and received net proceeds of $6,781,199. In connection with this private placement, the Company issued (i) 2,301,353 shares of its common stock together with investor warrants (“Investor Warrants”) to purchase up to 2,301,353 shares of common stock, and (ii) 1,302,251 pre-funded warrants (“Pre-Funded Warrants”) with each Pre-Funded Warrant exercisable for one share of common stock, together with Investor Warrants to purchase up to 1,302,251 shares of common stock. Each share of common stock and accompanying Investor Warrant were sold together at a combined offering price of $2.22 and each Pre-Funded Warrant and accompanying Investor Warrant were sold together at a combined offering price of $2.219. The Pre-Funded Warrants were immediately exercisable, at a nominal exercise price of $0.001, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Investor Warrants have an exercise price of $2.22 per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance and will expire five years from the date of issuance.

 

 

 

 9 

 

 

On April 28, 2022, the Company completed another private placement and received net proceeds of $16,752,915. In connection with this private placement, the Company issued (i) 2,472,820 shares of its common stock together with warrants (“April Warrants”) to purchase up to 4,945,640 shares of common stock, and (ii) 2,390,025 pre-funded warrants (“Pre-Funded Warrants”) with each Pre-Funded Warrant exercisable for one share of common stock, together with April Warrants to purchase up to 4,780,050 shares of common stock. Each share of common stock and accompanying two April Warrants were sold together at a combined offering price of $4.01 and each Pre-Funded Warrant and accompanying two April Warrants were sold together at a combined offering price of $4.009. The Pre-Funded Warrants were immediately exercisable, at a nominal exercise price of $0.001, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The April Warrants have an exercise price of $3.76 per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance and will expire five years from the date of issuance.

 

The Company declared no dividends through September 30, 2022.

 

Note 7 – Warrants

 

The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10 or ASC 815-40. Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.

 

During the nine months ended September 30, 2022, the Company completed three financing events, and in connection therewith, it issued warrants as follows: 

     
TYPE NUMBER EXERCISE PRICE EXPIRY DATE
Pre-Funded Warrants 3,692,276 $0.001 Unlimited
Tradeable Warrants 4,102,200 $2.22* February 2027
Investor Warrants 3,603,604 $2.22 March 2027    
April Warrants 9,725,690 $3.76 April 2027

 

* The Tradeable Warrants had an initial exercise price of $4.25, subject to adjustment. Upon the closing of the Company’s private placement on March 14, 2022, the exercise price of the Tradeable Warrants was reduced to $2.22, in accordance with the terms thereof.

 

During the nine months ended September 30, 2022, all of the Pre-Funded Warrants and a total of 3,138,507 Tradeable Warrants were exercised resulting in aggregate proceeds of $6,971,178 received by the Company. In addition, during the nine months ended September 30, 2022, a total of 2,802,703 Investor Warrants were exercised resulting in aggregate proceeds of $6,222,001 received by the Company.

 

The Company’s outstanding warrants at September 30, 2022 consisted of the following: 

     
TYPE NUMBER EXERCISE PRICE EXPIRY DATE
Pre-Funded Warrants None $0.001 Unlimited
Tradeable Warrants 963,693 $2.22 February 2027
Investor Warrants 800,901 $2.22 March 2027
April Warrants 9,725,690 $3.76 April 2027

 

 

 

 10 

 

 

Note 8 – Net Loss Per Common Share

 

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents.

 

Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, taking into consideration common stock equivalents.

 

In February 2022, the Company issued 4,102,200 Tradeable Warrants pursuant to the Company’s Public Offering. In March and April 2022, the Company issued 3,603,604 Investor Warrants and 9,725,690 April Warrants pursuant to two private placements. As of September 30, 2022, 3,138,507 Tradeable Warrants, 2,802,703 Investor Warrants, and -0- April Warrants were exercised, leaving 963,693 Tradeable Warrants, 800,901 Investor Warrants and 9,725,690 April Warrants outstanding. These warrants are dilutive and were included in the diluted earnings per share.

 

In March and April 2022, the Company issued and sold Pre-Funded Warrants to purchase an aggregate of 3,692,276 shares of common stock at a nominal exercise price of $0.001 per share (see Note 3). During the nine months ended September 30, 2022, all of these warrants were exercised and therefore had no remaining dilutive effect.

 

Note 9 – Management and Director Compensation

 

The Company paid its officers cash compensation totaling $595,000 and $105,000 and $1,095,000 and $130,000 for the three and nine month periods ended September 30, 2022 and 2021, respectively. Of these amounts attributable to the Company’s CEO, as of September 30, 2021 $110,000 was paid to Advanomics Corporation, a company controlled by the CEO of the Company. In addition, the Company issued 300,000 shares of common stock valued at $918,000 to its officers during the three months ended September 30, 2021. The value of these shares was based upon the closing price of the Company’s common stock of $3.06 on the issuance date.

 

The Company paid its directors cash compensation totaling $100,000 and $200,000 for the three and nine month periods ended September 30, 2022 and 2021, respectively.

 

Note 10 – Subsequent Events

 

On October 20, 2022, the Company acquired all of the outstanding shares of Nora Pharma Inc., a Canadian generic pharmaceuticals company. The total purchase price of $30,000,000 Canadian (approximately $21,900,000 USD) was paid by paying $20,000,000 Canadian (approximately $14,600,000 USD) in cash, issuing 3,700,000 shares of the Company’s Common Stock valued at $5,000,000 Canadian (approximately $3,650,000 USD), and $5,000,000 Canadian (approximately $3,650,000 USD) which may be paid in the future as an earn-out amount based on target sales. Through the contingent earn-out, the seller, Mr. Malek Chamoun, has the opportunity to earn up to $5,000,000 CAD (approximately $3,650,000 USD) in the form of twenty (20) payments of $250,000 CAD for every $1,000,000 CAD increase in gross sales above Nora Pharma’s June 30, 2022 gross sales, provided that his employment with the Company is not terminated pursuant to the Company’s Employment Agreement with him.

 

 

 

 11 

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

The following discussion should be read in conjunction with our consolidated financial statements and notes thereto included herein. This discussion includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. The statements regarding Sunshine Biopharma, Inc. contained in this Report that are not historical in nature, particularly those that utilize terminology such as “may,” “will,” “should,” “likely,” “expects,” “anticipates,” “estimates,” “believes” or “plans,” or comparable terminology, are forward-looking statements based on current expectations and assumptions, and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to us that could cause such material differences are identified in this report and in our annual report on Form 10-K for the year ended December 31, 2021. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law. You are advised, however, to consult any future disclosures we make on related subjects in future reports to the SEC.

 

Overview

 

We are a pharmaceutical company focusing on the research and development of proprietary drugs including our anticancer compound Adva-27a, our anticancer K1.1 mRNA molecules, and anti-coronavirus lead compound, SBFM-PL4.

 

In addition, we develop science-based nutritional supplements through our wholly owned Canadian subsidiary, Sunshine Biopharma Canada Inc. (“Sunshine Canada”), and we currently sell one nutritional supplement product, Essential 9tm.

 

On October 20, 2022, we completed the acquisition of Nora Pharma Inc. (“Nora Pharma”), a Canadian generic pharmaceuticals company. Based in the greater Montreal area, Nora Pharma has 36 employees and operates in a 15,000 square foot facility certified by Health Canada. Nora Pharma currently offers over 50 pharmaceutical products, including generic prescription drugs, over-the-counter products and biosimilars. Nora Pharma sales were $10.7 million for its fiscal year ended June 30, 2022 and its net income for this period was $0.3 million (USD).

 

Proprietary Drug Development Operations

 

SBFM-PL4 Anti-Coronavirus Treatment

 

The following is a summary of the development to date of our coronavirus treatment project:

 

  · On May 22, 2020, we filed a patent application in the United States for a new treatment for Coronavirus infections. Our patent application covers composition subject matter pertaining to small molecules for inhibition of the Coronavirus main protease (Mpro) and papain-like protease (PLpro). Both enzymes are essential for viral replication. In addition to being involved in maturation of specific viral proteins, PLpro is responsible for suppression of the human immune system making the virus more virulent. The small molecules covered by the patent application were designed by Dr. Steve N. Slilaty, our chief executive officer. The patent application has a priority date of May 22, 2020.
     
  · In August 2020, we completed the synthesis of four different potential inhibitors of PLpro. These compounds are based on the technology described in our patent application filed on May 22, 2020.
     
  · In September 2020, we completed the screening of our four compounds and subsequently identified a lead Anti-Coronavirus drug candidate (SBFM-PL4). The screening which pinpointed the lead compound was performed at the University of Georgia, College of Pharmacy.
     
  · The next steps in our SBFM-PL4 drug development plan will involve conducting additional in vitro studies followed by cell culture assays and assessment in Coronavirus infected mice before entering human clinical trials.
     
  · In February 2022, we expanded our search for additional PLpro inhibitors by entering into a research agreement with the University of Arizona for the purposes of conducting research focused on determining the in vivo safety, pharmacokinetics, and dose selection properties of three University of Arizona owned PLpro inhibitors, to be followed by efficacy testing in mice infected with SARS-CoV-2 (the “Research Project”). Under the agreement, the University of Arizona granted the Company a first option to negotiate a commercial, royalty-bearing license for all intellectual property developed by University of Arizona personnel under the Research Project. In addition, the Company and the University of Arizona entered into an Option Agreement whereby the Company was granted a first option to negotiate a royalty-bearing commercial license for the underlying technology of the Research Project. Intending to move forward with the technology, we submitted a Notice of Option Exercise to the University of Arizona on September 13, 2022.

 

 

 

 12 

 

 

Adva-27a Anticancer Compound

 

In the area of oncology, our proprietary drug development activities have been focused on the development of a small molecule called Adva-27a for the treatment of aggressive forms of cancer. A Topoisomerase II inhibitor, Adva-27a has been shown to be effective at destroying Multidrug Resistant Cancer cells including Pancreatic Cancer cells, Breast Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Sunshine Biopharma is direct owner of all issued patents pertaining to Adva-27a including U.S. Patents Number 8,236,935 and 10,272,065.

 

 

 

Figure 1

 

Adva-27a is a GEM-difluorinated C-glycoside derivative of Podophyllotoxin (see Figure 1). Another derivative of Podophyllotoxin called Etoposide is currently on the market and is used to treat various types of cancer including leukemia, lymphoma, testicular cancer, lung cancer, brain cancer, prostate cancer, bladder cancer, colon cancer, ovarian cancer, liver cancer and several other forms of cancer. Etoposide is one of the most widely used anticancer drugs. Adva-27a and Etoposide are similar in that they both attack the same target in cancer cells, namely the DNA unwinding enzyme, Topoisomerase II. Unlike Etoposide however, Adva-27a is able to penetrate and destroy Multidrug Resistant Cancer cells. In addition, Adva-27a has been shown to have distinct and more desirable biological and pharmacological properties compared to Etoposide. In side-by-side studies using Multidrug Resistant Breast Cancer cells and Etoposide as a reference, Adva-27a showed markedly greater cell killing activity (see Figure 2).

 

 

 

Figure 2

 

 

 

 13 

 

 

The next sequence of steps in our Adva-27a development program includes:

 

  · GMP Manufacturing of 2 kilograms for use in IND-Enabling Studies and Phase I Clinical Trials
     
  · IND-Enabling Studies
     
  · Regulatory Filing (Fast-Track status anticipated)
     
  · Phase I Clinical Trials (Pancreatic Cancer indication)

 

Adva-27a’s initial indication will be pancreatic cancer for which there are currently little or no treatment options available. We are planning to conduct our clinical trials at McGill University’s Jewish General Hospital in Montreal, Canada. All aspects of the clinical trials in Canada will employ FDA standards at all levels.

 

According to the American Cancer Society, nearly 1.5 million new cases of cancer are diagnosed in the U.S. each year. While particularly effective against Multidrug Resistant Cancer, we believe Adva-27a can potentially treat all cancer types, particularly those in which Topoisomerase II has been amplified. We believe that upon successful completion of Phase I Clinical Trials we may receive one or more offers from large pharmaceutical companies to purchase or license our drug. However, there are no assurances that our Phase I Trials will be successful, or if successful, that any pharmaceutical companies will make an acceptable offer to us. In the event we do not consummate such a transaction, we will require significant capital in order to secure regulatory approval, manufacture and market our new drug on our own.

 

K1.1 Anti-cancer mRNA

 

In June 2021, we initiated a new research project in which we set out to determine if certain mRNA molecules can be used as anti-cancer agents. The data collected to date have shown that a selected group of mRNA molecules are capable of destroying cancer cells in vitro including multidrug resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2). Other studies using non-transformed (normal) human cells (HMEC cells) showed that these mRNA molecules had little cytotoxic effects. These new mRNA molecules, bearing the laboratory name K1.1, are readily adaptable for delivery into patients using the mRNA vaccine technology. In April 2022, we filed a provisional patent application in the United States covering the subject mRNA molecules. We are currently in discussion with several potential partners for the purposes of formulating our K1.1 mRNA molecules into lipid nanoparticles (K1.1::LNP). Using the K1.1::LNP formulations, we plan to commence mice xenograft studies within approximately the next twelve months.

 

Nutritional Supplements Operations

 

Our wholly owned Canadian subsidiary, Sunshine Canada, focuses on the development and marketing of science-based nutritional supplements. In December 2018, we completed the development of our first nutritional supplement product which we named Essential 9™. On December 14, 2018, Health Canada issued NPN 80089663 through which it authorized us to manufacture and sell the Essential 9™ product. Our Essential 9™ nutritional supplement product was originally launched as a tablet and has now been reformatted into vegan capsules. Our Essential 9tm capsules contain a balanced formula of the 9 Essential Amino Acids that the human body cannot make. Essential Amino Acids are 9 out of the 20 amino acids required for protein synthesis. Proteins are involved in all body functions – From the musculature and immune system to hormones and neurotransmitters. Like vitamins, Essential Amino Acids cannot be made by the human body and must be obtained through diet. Deficiency in one or more of the 9 Essential Amino Acids can lead to loss of muscle mass, fatigue, weight gain and reduced ability to build muscle mass in athletes. Our Essential 9™ provides all 9 Essential Amino Acids in freeform and in the proportions recommended by Health Canada. Essential 9™ is currently available on Amazon.com and Amazon.ca. Figure 3 below shows our reformatted 60-Capsule Essential 9™ product.

 

 

 

 14 

 

 

 

 

Figure 3

  

In November 2019, we received Health Canada approval for another nutritional supplement, a new Calcium-Vitamin D tablet. Health Canada issued NPN 80093432 through which it authorized us to manufacture and sell the new Calcium-Vitamin D supplement under the brand name Essential Calcium-Vitamin D™. Vitamin D is a group of steroid-like molecules responsible for increasing intestinal absorption of calcium, magnesium, and phosphate. They are also involved in multiple other biological functions, including proper functioning of the immune system, promoting healthy growth of bone, and reduction of inflammation. The most important compounds in this group are ergocalciferol (Vitamin D2) and cholecalciferol (Vitamin D3). Sunshine Biopharma’s Essential Calcium-Vitamin D™ tablets contain both of these compounds as well as calcium for optimum health benefits. We are considering potentially launching this product in 2023.

  

Results of Operations

 

Comparison of results of operations for the three months ended September 30, 2022 and 2021

 

During the three months ended September 30, 2022, we generated revenues of $132,808, compared to revenue of $50,376 for the three months ended September 30, 2021. The increase is attributable to increased marketing efforts. All of these revenues were generated from our science-based nutritional supplements operations. The direct cost for generating these revenues was $65,783 for the three months ended September 30, 2022 (49.5%), compared to $19,506 (38.7%) for the three months ended September 30, 2021. The increase in cost of sales in 2022 is due to increases in manufacturing cost. Our gross profit increased to $67,025 for the three months ended September 30, 2022, compared to a gross profit of $30,870 for the same period in 2021.

 

General and administrative expenses during the three month period ended September 30, 2022 were $1,785,005 compared to $527,129 during the three month period ended September 30, 2021, an increase of $1,257,876. Overall, we incurred a loss of $1,717,980 from our operations in the three month period ended September 30, 2022, compared to a loss from operations of $496,259 in the similar period of 2021.

 

In addition, we had interest income of $260,938, interest expense of $2, and debt forgiveness of $0, during the three months ended September 30, 2022, compared to interest income of $0, interest expense of $46,849, and debt forgiveness of $7,688, during the three months ended September 30, 2021. This was primarily due to the transitioning of our financing from convertible debt to equity. We incurred no losses related to debt conversion during the three months ended September 30, 2022, compared to $3,504,000 in losses arising from debt conversion during the three months ended September 30, 2021. This was also due to the transitioning of our financing from convertible debt to equity.

 

As a result, we incurred a net loss of $1,457,019 for the three month period ended September 30, 2022, compared to a net loss of $4,039,383 for the three month period ended September 30, 2021.

 

 

 

 15 

 

 

Comparison of results of operations for the nine months ended September 30, 2022 and 2021

 

During the nine months ended September 30, 2022, we generated revenues of $405,760, compared to revenue of $143,308 for the nine months ended September 30, 2021. The increase is attributable to increased marketing efforts. All of these revenues were generated from our science-based nutritional supplements operations. The direct cost for generating these revenues was $200,311 for the nine months ended September 30, 2022 (49.4%), compared to $56,541 (39.5%) for the nine months ended September 30, 2021. The increase in cost of sales in 2022 is due to increases in manufacturing cost. Our gross profit increased to $205,449 for the nine months ended September 30, 2022, compared to a gross profit of $86,767 for the same period in 2021.

 

General and administrative expenses during the nine month period ended September 30, 2022 were $3,842,589 compared to $2,247,270 during the nine month period ended September 30, 2021, an increase of $1,595,319. Overall, we incurred a loss of $3,637,140 from our operations in the nine month period ended September 30, 2022, compared to a loss from operations of $2,160,503 in the similar period of 2021.

 

In addition, we had interest income of $406,984, interest expense of $12,866, and debt forgiveness of $10,852 during the nine months ended September 30, 2022, compared to interest income of $0, interest expense of $292,188, and debt forgiveness of $58,940 during the nine months ended September 30, 2021. This was primarily due to the transitioning of our financing from convertible debt to equity. We incurred no losses related to debt conversion during the nine months ended September 30, 2022, compared to $10,709,843 in losses arising from debt conversion during the nine months ended September 30, 2021. This was also due to the transitioning of our financing from convertible debt to equity.

 

As a result, we incurred a net loss of $3,232,125 for the nine month period ended September 30, 2022, compared to a net loss of $13,103,563 for the nine month period ended September 30, 2021.

  

Liquidity and Capital Resources

 

As of September 30, 2022, we had cash and cash equivalents of $40,555,931.

  

Net cash used in operating activities was $3,001,746 during the nine months ended September 30, 2022, compared to $1,517,015 during the nine month period ended September 30, 2021. The increase was a result of increased marketing and R&D activities as well as increases in professional fees related to becoming a Nasdaq listed company. 

 

Cash flows provided by financing activities were $41,561,363 for the nine months ended September 30, 2022, compared to $2,928,339 for the nine month period ended September 30, 2021. The increase was a result of three financing events completed in February, March and April 2022, as well as warrant exercises.

 

Cash flows used in investing activities were $0 for the nine months ended September 30, 2022 and September 30, 2021.

 

We are not generating adequate revenues from our operations to fully implement our business plan as set forth herein. On February 17, 2022, we received net proceeds of approximately $6.8 million from the sale of common stock and warrants in an underwritten public offering. On March 14, 2022, we received net proceeds of approximately $6.8 million from the sale of common stock and warrants in a private placement. On April 28, 2022, we received net proceeds of approximately $16.8 million from the sale of common stock and warrants in a private placement. We believe our existing cash will be sufficient to fund our operations, including general and administrative expenses, expanded research and development activities, and nutritional supplement business, for the next 24 months. There is no assurance our estimates will be accurate. We have no committed sources of capital and we anticipate that we will need to raise additional capital in the future, including for further research and development activities and possibly clinical trials, as well as expansion of our generic pharmaceutical operations arising from the Nora Pharma acquisition. Additional capital may not be available on terms acceptable to us, or at all.

 

 

 

 16 

 

 

Critical Accounting Policies and Estimates

 

Critical Accounting Estimates

 

The discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.  Actual results may differ from these estimates under different assumptions or conditions.

 

For a detailed list of significant accounting policies, please see our annual report on Form 10-K for the fiscal year ended December 31, 2021, including our financial statements and notes thereto included therein as filed with the SEC on March 21, 2022,

  

Recently Adopted Accounting Standards

 

In February 2020, the FASB issued ASU 2020-02, Financial Instruments-Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842) which amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments will be effective for the Company for interim and annual periods in fiscal years beginning after December 15, 2022. The Company believes the adoption will modify the way the Company analyzes financial instruments, but it does not anticipate a material impact on results of operations. The Company is in the process of determining the effects adoption will have on its consolidated financial statements.

 

In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40), (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU2020-06 amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is evaluating the impact of this guidance on its unaudited consolidated financial statements.

 

Off Balance-Sheet Arrangements

 

None.

 

 

 

 

 17 

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

We are a smaller reporting company and are not required to provide the information under this item.

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of the end of the period covered by this report.

 

These controls are designed to ensure that information required to be disclosed in the reports we file or submit pursuant to the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission, and that such information is accumulated and communicated to our management, including our CEO and CFO, to allow timely decisions regarding required disclosure.

 

Based on this evaluation, our management, including our CEO and CFO concluded that our disclosure controls and procedures were effective as of September 30, 2022, at reasonable assurance levels.

 

Changes in Internal Control Over Financial Reporting

 

There were no changes in our internal control over financial reporting during the quarter ended September 30, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 

 

 

 

 18 

 

 

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

We are not party to, and our property is not the subject of, any material legal proceedings.

 

Item 1A. Risk Factors.

 

We are a smaller reporting company and are not required to provide the information under this item.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

None.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not Applicable.

 

Item 5. Other Information.

 

None.

 

Item 6. Exhibits.

 

Exhibit No.   Description
     
31.1   Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
31.2   Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2022*
32.1   Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*
101   Inline XBRL Document Set for the financial statements and accompanying notes in Part I, Item 1, of this Quarterly Report on Form 10-Q.*
104   Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set.*

 

  * Filed herewith.

 

 

 

 

 19 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized, on November 7, 2022.

 

  SUNSHINE BIOPHARMA, INC.  
       
  By: /s/ Dr. Steve N. Slilaty  
    Dr. Steve N. Slilaty  
    Chief Executive Officer (principal executive officer)  
       
       
  By: /s/ Camille Sebaaly  
   

Camille Sebaaly

Chief Financial Officer (principal financial and accounting officer)

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 20 

 

 EX-31.1 2 sunshine_ex3101.htm CERTIFICATION

Exhibit 31.1

 

CERTIFICATION PURSUANT TO

18 USC, SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

 

I, Dr. Steve N. Slilaty, certify that:

 

  1. I have reviewed this quarterly report on Form 10-Q of Sunshine Biopharma, Inc.

 

  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

 

  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.

 

  4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedure to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and

 

  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Dated: November 7, 2022

/s/ Dr. Steve N. Slilaty

Dr. Steve N. Slilaty, Chief Executive Officer

 

 EX-31.2 3 sunshine_ex3102.htm CERTIFICATION

Exhibit 31.2

 

CERTIFICATION PURSUANT TO

18 USC, SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

 

I, Camille Sebaaly, certify that:

 

  1. I have reviewed this quarterly report on Form 10-Q of Sunshine Biopharma, Inc.

 

  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

 

  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.

 

  4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedure to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and

 

  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Dated: November 7, 2022

/s/ Camille Sebaaly

Camille Sebaaly, Chief Financial Officer

 

 EX-32.1 4 sunshine_ex3201.htm CERTIFICATION

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 USC, SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with this quarterly report of Sunshine Biopharma, Inc. (the “Company”) on Form 10-Q for the quarterly period ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, the undersigned, in the capacities and on the date indicated below, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:

 

  1. The Report fully complies with the requirements of Rule 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Dated: November 7, 2022

/s/ Dr. Steve N. Slilaty

Dr. Steve N. Slilaty, Chief Executive Officer

   
Dated: November 7, 2022

/s/ Camille Sebaaly

Camille Sebaaly, Chief Financial Officer

 

 GRAPHIC 5 s1.jpg GRAPHIC begin 644 s1.jpg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end GRAPHIC 6 s2.jpg GRAPHIC begin 644 s2.jpg M_]C_X 02D9)1@ ! 0$ > !X #_X0-217AI9@ 34T *@ @ !5$ 0 M ! %$! , ! $ %$" $ , 2E$# $ ! %$$ M $ !_ #, &8 )D ,P /\ *P *S, *V8 *YD M*\P *_\ 50 53, 568 59D 5

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end GRAPHIC 7 s3.jpg GRAPHIC begin 644 s3.jpg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sbfm-20220930.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statement of Shareholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Nature of Business link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Impact of Coronavirus (COVID-19) Pandemic link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Reverse Stock Splits link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Shareholders’ Equity link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Warrants link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Net Loss Per Common Share link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Management and Director Compensation link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Nature of Business (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Reverse Stock Splits (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Shareholders’ Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Warrants (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Warrants (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Net Loss Per Common Share (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Management and Director Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 sbfm-20220930_cal.xml XBRL CALCULATION FILE EX-101.DEF 10 sbfm-20220930_def.xml XBRL DEFINITION FILE EX-101.LAB 11 sbfm-20220930_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Warrant [Member] Class of Stock [Axis] Series B Preferred Stock [Member] Additional Paid-in Capital [Member] Preferred Stock [Member] Comprehensive Income [Member] Retained Earnings [Member] Securities Financing Transaction [Axis] Aegis Offering [Member] Tradeable Warrants [Member] Private Placement [Member] Investor Warrants 1 [Member] Pre Funded Warrants [Member] Investor Warrants 2 [Member] Pre Funded Warrants 1 [Member] Award Type [Axis] Transaction Type [Axis] First Reverse Stock Split [Member] Second Reverse Stock Split [Member] Third Reverse Stock Split [Member] Long-Term Debt, Type [Axis] Note Payable 20211 [Member] Note Payable 20212 [Member] Note Payable 20213 [Member] Investor Warrants [Member] April Warrants [Member] Investor Warrants And April Warrants [Member] Related Party [Axis] Advanomics Corporation [Member] Officers And Directors [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current Assets: Cash and cash equivalents Accounts receivable Inventory Prepaid expenses Deposits Total Current Assets Equipment, net TOTAL ASSETS LIABILITIES AND SHAREHOLDERS' EQUITY Current Liabilities: Accounts payable and accrued expenses Interest payable Total Current Liabilities Long-term portion of notes payable TOTAL LIABILITIES SHAREHOLDERS' EQUITY Preferred Stock, Series B $0.10 par value per share; 1,000,000 shares authorized; 10,000 and 1,000,000 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively Common Stock, $0.001 par value per share; 3,000,000,000 shares authorized; 18,885,632 and 2,591,240 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively Capital paid in excess of par value Accumulated comprehensive (loss) Accumulated (deficit) TOTAL SHAREHOLDERS' EQUITY TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY Preferred Stock, Par or Stated Value Per Share Preferred Stock, Shares Authorized Preferred Stock, Shares Outstanding Preferred Stock, Shares Issued Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Common Stock, Shares, Outstanding Common Stock, Shares, Issued Income Statement [Abstract] Revenues Cost of sales Gross profit General and Administrative Expenses: Accounting Advertising and Marketing Consulting Legal Office Officer and director remuneration Patent fees R&D Depreciation Total General and Administrative Expenses (Loss) from operations Other Income (Expense): Foreign exchange gain Interest income Interest expense Debt forgiveness Loss on debt conversions Total Other Income (Expense) Net (loss) before income taxes Provision for income taxes Net (Loss) (Loss) from foreign exchange translation Comprehensive (Loss) Basic (loss) per common share Weighted Average Common Shares Outstanding (Basic) Statement of Cash Flows [Abstract] Cash Flows From Operating Activities: Net (Loss) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Foreign exchange (gain) loss Stock issued for services Stock issued for payment interest Loss on debt conversion Debt forgiveness Decrease in accounts receivable (Increase) in inventory (Increase) decrease in prepaid expenses Increase (decrease) in Accounts Payable & accrued expenses Increase (decrease) in interest payable Net Cash Flows (Used) in Operations Cash Flows From Financing Activities: Proceeds public offerings, net Purchase of preferred shares Payments of notes payable Net Cash Flows Provided by Financing Activities Cash and Cash Equivalents at Beginning of Period Net increase in cash and cash equivalents Effect of exchange rate changes on cash Foreign currency translation adjustment Cash and Cash Equivalents at End of Period Supplementary Disclosure of Cash Flow Information: Stock issued for note conversions including interest Cash paid for interest Cash paid for income taxes Beginning balance, value Beginnig Balance shares Common stock and pre-funded warrants issued in an underwritten public and private offerings, net of issuance costs [custom:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenpublicAndPrivateOfferingsNetOfIssuanceCostsShares] Exercise of warrants Exercise of warrants, shares Preferred stock purchased from related party Preferred stock purchased from related party, shares Net (loss) Common stock issued for the reduction of note payable and payment of interest Common stock issued for the reduction of note payable and payment of interest shares Common stock issued for services Common stock issued for services shares Ending balance, value Ending Balance shares Organization, Consolidation and Presentation of Financial Statements [Abstract] Nature of Business Accounting Policies [Abstract] Basis of Presentation Impact Of Coronavirus Covid-19 Pandemic Impact of Coronavirus (COVID-19) Pandemic Reverse Stock Splits Reverse Stock Splits Debt Disclosure [Abstract] Notes Payable Equity [Abstract] Shareholders’ Equity Warrants Warrants Earnings Per Share [Abstract] Net Loss Per Common Share Management And Director Compensation Management and Director Compensation Subsequent Events [Abstract] Subsequent Events Warrants issued with financing Schedule of outstanding warrants Securities Financing Transaction [Table] Securities Financing Transaction [Line Items] Proceeds from Issuance or Sale of Equity Stock Issued During Period, Shares, New Issues Warrants issued new, shares Stock Redeemed or Called During Period, Shares Proceeds from Issuance of Private Placement Class of Warrant or Right, Exercise Price of Warrants or Rights Offsetting Assets [Table] Offsetting Assets [Line Items] Stockholders' Equity, Reverse Stock Split Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Line Items] Notes Payable Interest Payable Face Value Interest Rate Maturity Date Interest Paid, Including Capitalized Interest, Operating and Investing Activities Repayments of notes payable Schedule of Stock by Class [Table] Class of Stock [Line Items] Proceeds from Issuance Initial Public Offering Redeemed shares Redemption price Proceeds from Issuance of private placement Warrants exercise price Dividends Number of shares Warrant Expiration Date Class of Warrant or Right, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Proceeds from Warrant Exercises Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] [custom:WarrantsIssuedNewShares] Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items] Salary and Wage, Excluding Cost of Good and Service Sold Stock Issued During Period, Shares, Issued for Services Stock Issued During Period, Value, Issued for Services Noninterest Expense Directors Fees Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Gross Profit General and Administrative Expense Operating Income (Loss) Interest Expense Nonoperating Income (Expense) Income Tax Expense (Benefit) Net Income (Loss) Attributable to Parent Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense Net Cash Provided by (Used in) Operating Activities ProceedsPublicOfferingNet Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Shares, Outstanding PreferredStockPurchasedFromRelatedPartyValue ReverseStockSplitTextBlock WarrantsDisclosureTextBlock Notes Payable [Default Label] EX-101.PRE 12 sbfm-20220930_pre.xml XBRL PRESENTATION FILE XML 13 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover - shares
 9 Months Ended
Sep. 30, 2022
Nov. 07, 2022
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Sep. 30, 2022  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2022  
Current Fiscal Year End Date --12-31  
Entity File Number 001-41282  
Entity Registrant Name SUNSHINE BIOPHARMA, INC.  
Entity Central Index Key 0001402328  
Entity Tax Identification Number 20-5566275  
Entity Incorporation, State or Country Code CO  
Entity Address, Address Line One 6500 Trans-Canada Highway  
Entity Address, Address Line Two 4th Floor  
Entity Address, Address Line Three Pointe-Claire  
Entity Address, City or Town Quebec  
Entity Address, Country CA  
Entity Address, Postal Zip Code H9R 0A5  
City Area Code (514)  
Local Phone Number 426-6161  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   22,585,632
Common Stock [Member]    
Title of 12(b) Security Common Stock  
Trading Symbol SBFM  
Security Exchange Name NASDAQ  
Warrant [Member]    
Title of 12(b) Security Common Stock Purchase Warrants  
Trading Symbol SBFMW  
Security Exchange Name NASDAQ  

XML 14 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Current Assets:    
Cash and cash equivalents $ 40,555,931 $ 2,045,167
Accounts receivable 22 7,798
Inventory 269,641 105,650
Prepaid expenses 27,390 29,625
Deposits 7,590 7,590
Total Current Assets 40,860,574 2,195,830
Equipment, net 3,770 7,061
TOTAL ASSETS 40,864,344 2,202,891
Current Liabilities:    
Accounts payable and accrued expenses 480,209 42,942
Interest payable 0 48,287
Total Current Liabilities 480,209 91,229
Long-term portion of notes payable 0 1,900,000
TOTAL LIABILITIES 480,209 1,991,229
SHAREHOLDERS' EQUITY    
Preferred Stock, Series B $0.10 par value per share; 1,000,000 shares authorized; 10,000 and 1,000,000 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively 1,000 100,000
Common Stock, $0.001 par value per share; 3,000,000,000 shares authorized; 18,885,632 and 2,591,240 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively 18,886 2,591
Capital paid in excess of par value 76,331,451 32,787,384
Accumulated comprehensive (loss) (79,903) (23,139)
Accumulated (deficit) (35,887,299) (32,655,174)
TOTAL SHAREHOLDERS' EQUITY 40,384,135 211,662
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 40,864,344 $ 2,202,891
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Sep. 30, 2022
Dec. 31, 2021
Common Stock, Par or Stated Value Per Share $ 0.001 $ 0.001
Common Stock, Shares Authorized 3,000,000,000 3,000,000,000
Common Stock, Shares, Outstanding 18,885,632 2,591,240
Common Stock, Shares, Issued 18,885,632 2,591,240
Series B Preferred Stock [Member]    
Preferred Stock, Par or Stated Value Per Share $ 0.10 $ 0.10
Preferred Stock, Shares Authorized 1,000,000 1,000,000
Preferred Stock, Shares Outstanding 10,000 1,000,000
Preferred Stock, Shares Issued 10,000 1,000,000
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]        
Revenues $ 132,808 $ 50,376 $ 405,760 $ 143,308
Cost of sales 65,783 19,506 200,311 56,541
Gross profit 67,025 30,870 205,449 86,767
General and Administrative Expenses:        
Accounting 122,913 35,000 237,773 96,200
Advertising and Marketing 217,666 0 400,386 0
Consulting 162,852 20,598 270,033 53,168
Legal 142,883 56,923 388,238 159,074
Office 76,818 58,959 449,730 159,762
Officer and director remuneration 695,000 130,000 1,305,000 1,173,927
Patent fees 3,584 1 15,148 14,571
R&D 362,500 222,465 770,095 581,011
Depreciation 789 3,183 6,186 9,557
Total General and Administrative Expenses 1,785,005 527,129 3,842,589 2,247,270
(Loss) from operations (1,717,980) (496,259) (3,637,140) (2,160,503)
Other Income (Expense):        
Foreign exchange gain 25 37 45 31
Interest income 260,938 0 406,984 0
Interest expense (2) (46,849) (12,866) (292,188)
Debt forgiveness 0 7,688 10,852 58,940
Loss on debt conversions 0 (3,504,000) 0 (10,709,843)
Total Other Income (Expense) 260,961 (3,543,124) 405,015 (10,943,060)
Net (loss) before income taxes (1,457,019) (4,039,383) (3,232,125) (13,103,563)
Provision for income taxes 0 0 0 0
Net (Loss) (1,457,019) (4,039,383) (3,232,125) (13,103,563)
(Loss) from foreign exchange translation (45,126) (5,839) (56,764) (14,604)
Comprehensive (Loss) $ (1,502,145) $ (4,045,222) $ (3,288,889) $ (13,118,167)
Basic (loss) per common share $ (0.08) $ (1.59) $ (0.26) $ (5.73)
Weighted Average Common Shares Outstanding (Basic) 18,885,632 2,542,640 12,789,733 2,287,682
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash Flows From Operating Activities:    
Net (Loss) $ (3,232,125) $ (13,103,563)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 6,186 9,557
Foreign exchange (gain) loss 45 (31)
Stock issued for services 0 918,000
Stock issued for payment interest 0 38,201
Loss on debt conversion (0) 10,709,843
Debt forgiveness (10,852) (58,940)
Decrease in accounts receivable 7,776 787
(Increase) in inventory (163,991) (47,539)
(Increase) decrease in prepaid expenses 2,235 (22,268)
Increase (decrease) in Accounts Payable & accrued expenses 437,267 (13,778)
Increase (decrease) in interest payable (48,287) 52,716
Net Cash Flows (Used) in Operations (3,001,746) (1,517,015)
Cash Flows From Financing Activities:    
Proceeds public offerings, net 43,560,363 3,318,500
Purchase of preferred shares (99,000) 61,500
Payments of notes payable (1,900,000) (451,661)
Net Cash Flows Provided by Financing Activities 41,561,363 2,928,339
Cash and Cash Equivalents at Beginning of Period 2,045,167 989,888
Net increase in cash and cash equivalents 38,559,617 1,411,324
Effect of exchange rate changes on cash (105,617) 0
Foreign currency translation adjustment 56,764 (14,604)
Cash and Cash Equivalents at End of Period 40,555,931 2,386,608
Supplementary Disclosure of Cash Flow Information:    
Stock issued for note conversions including interest 0 11,981,072
Cash paid for interest 61,151 155,081
Cash paid for income taxes $ 0 $ 0
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statement of Shareholders' Equity (Unaudited) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Preferred Stock [Member]
Comprehensive Income [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2020 $ 1,732 $ 19,165,029 $ 100,000 $ (2,871) $ (20,218,727) $ (954,837)
Beginnig Balance shares at Dec. 31, 2020 1,732,096   1,000,000      
Net (loss) (14,604) (13,103,563) (13,118,167)
Common stock issued for the reduction of note payable and payment of interest $ 518 11,980,554 11,981,072
Common stock issued for the reduction of note payable and payment of interest shares 518,370          
Common stock issued for services $ 300 917,700 918,000
Common stock issued for services shares 300,000          
Ending balance, value at Sep. 30, 2021 $ 2,550 32,063,283 $ 100,000 (17,475) (33,322,290) (1,173,932)
Ending Balance shares at Sep. 30, 2021 2,550,466   1,000,000      
Beginning balance, value at Jun. 30, 2021 $ 2,430 28,319,403 $ 100,000 (11,636) (29,282,907) (872,710)
Beginnig Balance shares at Jun. 30, 2021 2,430,466   1,000,000      
Net (loss) (5,839) (4,039,383) (4,045,222)
Common stock issued for the reduction of note payable and payment of interest $ 120 3,743,880 3,744,000
Common stock issued for the reduction of note payable and payment of interest shares 120,000          
Ending balance, value at Sep. 30, 2021 $ 2,550 32,063,283 $ 100,000 (17,475) (33,322,290) (1,173,932)
Ending Balance shares at Sep. 30, 2021 2,550,466   1,000,000      
Beginning balance, value at Dec. 31, 2021 $ 2,596 32,787,379 $ 100,000 (23,139) (32,655,174) 211,662
Beginnig Balance shares at Dec. 31, 2021 2,595,620   1,000,000      
Common stock and pre-funded warrants issued in an underwritten public and private offerings, net of issuance costs $ 6,657 30,360,528 30,367,185
[custom:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenpublicAndPrivateOfferingsNetOfIssuanceCostsShares] 6,656,526          
Exercise of warrants $ 9,633 13,183,544 13,193,177
Exercise of warrants, shares 9,633,486          
Preferred stock purchased from related party (99,000) (99,000)
Preferred stock purchased from related party, shares     (990,000)      
Net (loss) (56,764) (3,232,125) (3,288,889)
Ending balance, value at Sep. 30, 2022 $ 18,886 76,331,451 $ 1,000 (79,903) (35,887,299) 40,384,135
Ending Balance shares at Sep. 30, 2022 18,885,632   10,000      
Beginning balance, value at Jun. 30, 2022 $ 18,886 76,331,451 $ 1,000 (34,777) (34,430,280) 41,886,280
Beginnig Balance shares at Jun. 30, 2022 18,885,632   10,000      
Net (loss) (45,126) (1,457,019) (1,502,145)
Ending balance, value at Sep. 30, 2022 $ 18,886 $ 76,331,451 $ 1,000 $ (79,903) $ (35,887,299) $ 40,384,135
Ending Balance shares at Sep. 30, 2022 18,885,632   10,000      
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Nature of Business
 9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Business

Note 1 – Nature of Business

 

Sunshine Biopharma, Inc. (the “Company”) was originally incorporated under the name Mountain West Business Solutions, Inc. on August 31, 2006, in the State of Colorado. Until October 2009, the Company was operating as a business consultancy firm.

 

Effective October 15, 2009, the Company acquired Sunshine Biopharma, Inc. in a transaction classified as a reverse acquisition. Sunshine Biopharma, Inc. held an exclusive license to a new anticancer drug bearing the laboratory name, Adva-27a (the “License Agreement”). Upon completion of the reverse acquisition transaction, the Company changed its name to Sunshine Biopharma, Inc. and began operating as a pharmaceutical company focusing on the development of the licensed Adva-27a anticancer drug.

 

In December 2015, the Company acquired all issued (US Patent Number 8,236,935, and 10,272,065) and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029 for the Adva-27a anticancer compound from Advanomics Corporation, a related party, and terminated the License Agreement. In 2016, the remaining value of these patents was impaired. The Company is however continuing development of the Adva-27a anticancer drug covered by these patents.

 

In December 2018, the Company launched a Science-Based Nutritional Supplements product, Essential 9™, an over-the-counter capsule comprised of the nine (9) essential amino acids that the human body cannot make. Essential 9™ has been authorized for marketing by Health Canada under NPN 80089663.

 

On May 22, 2020, the Company filed a provisional patent application in the United States for a new treatment for Coronavirus infections. The Company’s patent application covers composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease, Mpro, an enzyme that is essential for viral replication. The patent application has a priority date of May 22, 2020. On April 30, 2021, the Company filed a PCT application containing new research results and extending coverage to include the Coronavirus Papain-Like protease, PLpro. The priority date of May 22, 2020 has been maintained in the newly filed PCT application. The Company’s lead Anti-Coronavirus compound arising from these patents bears the laboratory name SBFM-PL4.

 

On January 26, 2021, the Company received a Notice of Allowances from the Canadian Intellectual Property Office for a new patent application covering Adva-27a. The newly issued patent contains new subject matter and extends the proprietary protection of Adva-27a in Canada until 2033.

 

On March 9, 2021, the Company received a Notice of Allowance from the European Patent Office for a new patent application covering Adva-27a. The newly issued patent contains new subject matter and extends the proprietary protection of Adva-27a in Europe until 2033. The equivalent patent in the United States was issued in 2019 (US Patent Number 10,272,065).

 

On February 15, 2022, the Company entered into an underwriting agreement with Aegis Capital Corp. as underwriter, for the issuance and sale in an underwritten public offering of 1,882,353 Units, each consisting of one share of common stock and two warrants (“Tradeable Warrants”) to purchase shares of common stock at a public offering price of $4.25 per Unit for total gross proceeds of $8,000,000 (“Public Offering”). On February 17, 2022, the Public Offering closed and the Company received net proceeds of $6,833,071. Pursuant to the Public Offering, the Company issued and sold an aggregate of 1,882,353 shares of common stock and 4,102,200 Tradeable Warrants (including 337,494 Tradeable Warrants purchased at $0.01 per warrant resulting from partial exercise of the overallotment option granted to the underwriter). In connection with these transactions, the Company’s shares of common stock and Tradeable Warrants began trading on Nasdaq under the symbol “SBFM” for the common stock and “SBFMW” for the Tradeable Warrants.

 

On February 18, 2022, the Company entered into a research agreement (the “SRA”) with the University of Arizona for the purposes of conducting research focused on determining the in vivo safety, pharmacokinetics, and dose selection properties of three University of Arizona owned PLpro inhibitors, to be followed by efficacy testing in mice infected with SARS-CoV-2 (the “Research Project”). Under the SRA, the University of Arizona granted the Company a first option to negotiate a commercial, royalty-bearing license for all intellectual property developed by University of Arizona personnel under the Research Project. In addition, the Company and the University of Arizona entered into an Option Agreement whereby the Company was granted a first option to negotiate a royalty-bearing commercial license for the underlying technology of the Research Project. Intending to move forward with the technology, the Company submitted a Notice of Option Exercise to the University of Arizona on September 13, 2022.

 

On February 22, 2022, the Company redeemed 990,000 shares of the Series B Preferred Stock from the CEO of the Company at a redemption price equal to the stated value of $0.10 per share.

 

On March 14, 2022, the Company completed a private placement wherein the Company sold (i) 2,301,353 shares of its common stock together with warrants (the “Investor Warrants”) to purchase up to 2,301,353 shares of common stock, and (ii) 1,302,251 pre-funded warrants (“Pre-Funded Warrants”) with each Pre-Funded Warrant exercisable for one share of common stock, together with Investor Warrants to purchase up to 1,302,251 shares of common stock. Each share of common stock and accompanying Investor Warrant were sold together at a combined offering price of $2.22, and each Pre-Funded Warrant and accompanying Investor Warrant were sold together at a combined offering price of $2.219. The Company received approximately $8 million in gross proceeds, and $6,781,199 in net proceeds in this offering.

 

On April 28, 2022, the Company completed another private placement and received net proceeds of $16,752,915. In connection with this private placement, the Company issued (i) 2,472,820 shares of its common stock together with warrants (“April Warrants”) to purchase up to 4,945,640 shares of common stock, and (ii) 2,390,025 pre-funded warrants (“Pre-Funded Warrants”) with each Pre-Funded Warrant exercisable for one share of common stock, together with April Warrants to purchase up to 4,780,050 shares of common stock. Each share of common stock and accompanying two April Warrants were sold together at a combined offering price of $4.01, and each Pre-Funded Warrant and accompanying two April Warrants were sold together at a combined offering price of $4.01, and each Pre-Funded Warrant and accompanying two April Warrants were sold together at a combined offering price of $4.009. The Pre-Funded Warrants were immediately exercisable, at a nominal exercise price of $0.001, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The April Warrants have an exercise price of $3.76 per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance and will expire five years from the date of issuance.

 

On October 20, 2022, the Company acquired Nora Pharma Inc. (“Nora Pharma”), a Canadian generic pharmaceuticals company. Based in the greater Montreal area, Nora Pharma has 36 employees and operates in a 15,000 square foot facility certified by Health Canada. Nora Pharma currently offers over 50 pharmaceutical products, including generic prescription drugs, over-the-counter products and biosimilars. Nora Pharma sales were $10.7 million (USD) during its fiscal year ended June 30, 2022.

 
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Basis of Presentation
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation

Note 2 – Basis of Presentation

 

The unaudited financial statements of the Company for the nine month periods ended September 30, 2022 and 2021 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Regulation S-X. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. However, such information reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year. The balance sheet information as of December 31, 2021 was derived from the audited financial statements included in the Company's financial statements as of and for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 21, 2022. These financial statements should be read in conjunction with that report.

 
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
Impact of Coronavirus (COVID-19) Pandemic
 9 Months Ended
Sep. 30, 2022
Impact Of Coronavirus Covid-19 Pandemic  
Impact of Coronavirus (COVID-19) Pandemic

Note 3 – Impact of Coronavirus (COVID-19) Pandemic

 

In March 2020, the World Health Organization declared Coronavirus and its associated disease, COVID-19, a global pandemic. Conditions surrounding the Coronavirus outbreak have been and are continuing to evolve rapidly. Government authorities in the U.S. and around the world have implemented emergency measures to mitigate the spread of the virus. The outbreak and related mitigation measures have had and will continue to have a material adverse impact on the world economies and the Company's business activities. It is not possible for the Company to predict the duration or magnitude of the adverse conditions of the outbreak and their effects on the Company’s business or ability to raise funds. No adjustments have been made to the amounts reported in the Company's financial statements as a result of this matter.

 
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Reverse Stock Splits
 9 Months Ended
Sep. 30, 2022
Reverse Stock Splits  
Reverse Stock Splits

Note 4 – Reverse Stock Splits

 

Effective February 1, 2019, the Company completed a 20 to 1 reverse split of its common stock (the “First Reverse Stock Split”).

 

Effective April 6, 2020, the Company completed another 20 to 1 reverse split of its common stock (the “Second Reverse Stock Split”).

 

Effective February 9, 2022, the Company completed a 1 for 200 reverse split of its common stock (the “Third Reverse Stock Split”).

 

The Company's financial statements reflect the First, Second, and Third Reverse Stock Split on a retroactive basis for all periods presented and for all references to common stock, unless specifically stated otherwise.

 
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Notes Payable
 9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Notes Payable

Note 5 – Notes Payable

 

As of September 30, 2022 and December 31, 2021, the Company had $0 and $1,900,000, respectively in notes payable outstanding. At September 30, 2022 and December 31, 2021, total accrued interest on Notes Payable was $0 and $48,287, respectively.

 

The Company’s Notes Payable at December 31, 2021 consisted of the following:

 

On April 20, 2021, the Company received monies in exchange for a Note Payable having a Face Value of $500,000 with interest accruing at 5% due April 20, 2023. The Note was convertible after 180 days from issuance into common stock at a price equal to $0.30 per share. On February 17, 2022, the Company paid off the entire principal balance of this Note, together with accrued interest of $20,753 by making cash payment of $520,753.

 

On July 6, 2021, the Company received monies in exchange for a Note Payable having a Face Value of $900,000 with interest accruing at 5%, due July 6, 2023. The Note was convertible after 180 days from issuance into common stock at a price equal to $0.30 per share. On February 17, 2022, the Company paid off the entire principal balance of this Note, together with accrued interest of $27,863 by making cash payment of $927,863.

 

On August 18, 2021, the Company received monies in exchange for a Note Payable having a Face Value of $500,000 with interest accruing at 5%, due August 18, 2023. The Note was convertible after 180 days from issuance into common stock at a price equal to $0.30 per share. On February 17, 2022, the Company paid off the entire principal balance of this Note, together with accrued of $12,534 by making cash payment of $512,534.

 
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Shareholders’ Equity
 9 Months Ended
Sep. 30, 2022
Equity [Abstract]  
Shareholders’ Equity

Note 6 – Shareholders’ Equity

 

On February 17, 2022, the Company’s Public Offering closed and the Company received net proceeds of $6,833,071 from the offering. Pursuant to the Public Offering, the Company issued and sold an aggregate of 1,882,353 shares of common stock and 4,102,200 Tradeable Warrants (including 337,494 Tradeable Warrants resulting from partial exercise of the overallotment option granted to the underwriter).

 

On February 22, 2022, the Company redeemed 990,000 shares of Series B Preferred Stock from the CEO of the Company at a redemption price equal to the stated value of $0.10 per share.

 

On March 14, 2022, the Company completed a private placement and received net proceeds of $6,781,199. In connection with this private placement, the Company issued (i) 2,301,353 shares of its common stock together with investor warrants (“Investor Warrants”) to purchase up to 2,301,353 shares of common stock, and (ii) 1,302,251 pre-funded warrants (“Pre-Funded Warrants”) with each Pre-Funded Warrant exercisable for one share of common stock, together with Investor Warrants to purchase up to 1,302,251 shares of common stock. Each share of common stock and accompanying Investor Warrant were sold together at a combined offering price of $2.22 and each Pre-Funded Warrant and accompanying Investor Warrant were sold together at a combined offering price of $2.219. The Pre-Funded Warrants were immediately exercisable, at a nominal exercise price of $0.001, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Investor Warrants have an exercise price of $2.22 per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance and will expire five years from the date of issuance.

 

On April 28, 2022, the Company completed another private placement and received net proceeds of $16,752,915. In connection with this private placement, the Company issued (i) 2,472,820 shares of its common stock together with warrants (“April Warrants”) to purchase up to 4,945,640 shares of common stock, and (ii) 2,390,025 pre-funded warrants (“Pre-Funded Warrants”) with each Pre-Funded Warrant exercisable for one share of common stock, together with April Warrants to purchase up to 4,780,050 shares of common stock. Each share of common stock and accompanying two April Warrants were sold together at a combined offering price of $4.01 and each Pre-Funded Warrant and accompanying two April Warrants were sold together at a combined offering price of $4.009. The Pre-Funded Warrants were immediately exercisable, at a nominal exercise price of $0.001, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The April Warrants have an exercise price of $3.76 per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance and will expire five years from the date of issuance.

 

The Company declared no dividends through September 30, 2022.

 
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Warrants
 9 Months Ended
Sep. 30, 2022
Warrants  
Warrants

Note 7 – Warrants

 

The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10 or ASC 815-40. Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.

 

During the nine months ended September 30, 2022, the Company completed three financing events, and in connection therewith, it issued warrants as follows: 

     
TYPE NUMBER EXERCISE PRICE EXPIRY DATE
Pre-Funded Warrants 3,692,276 $0.001 Unlimited
Tradeable Warrants 4,102,200 $2.22* February 2027
Investor Warrants 3,603,604 $2.22 March 2027    
April Warrants 9,725,690 $3.76 April 2027

 

* The Tradeable Warrants had an initial exercise price of $4.25, subject to adjustment. Upon the closing of the Company’s private placement on March 14, 2022, the exercise price of the Tradeable Warrants was reduced to $2.22, in accordance with the terms thereof.

 

During the nine months ended September 30, 2022, all of the Pre-Funded Warrants and a total of 3,138,507 Tradeable Warrants were exercised resulting in aggregate proceeds of $6,971,178 received by the Company. In addition, during the nine months ended September 30, 2022, a total of 2,802,703 Investor Warrants were exercised resulting in aggregate proceeds of $6,222,001 received by the Company.

 

The Company’s outstanding warrants at September 30, 2022 consisted of the following: 

     
TYPE NUMBER EXERCISE PRICE EXPIRY DATE
Pre-Funded Warrants None $0.001 Unlimited
Tradeable Warrants 963,693 $2.22 February 2027
Investor Warrants 800,901 $2.22 March 2027
April Warrants 9,725,690 $3.76 April 2027

 
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net Loss Per Common Share
 9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Net Loss Per Common Share

Note 8 – Net Loss Per Common Share

 

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents.

 

Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, taking into consideration common stock equivalents.

 

In February 2022, the Company issued 4,102,200 Tradeable Warrants pursuant to the Company’s Public Offering. In March and April 2022, the Company issued 3,603,604 Investor Warrants and 9,725,690 April Warrants pursuant to two private placements. As of September 30, 2022, 3,138,507 Tradeable Warrants, 2,802,703 Investor Warrants, and -0- April Warrants were exercised, leaving 963,693 Tradeable Warrants, 800,901 Investor Warrants and 9,725,690 April Warrants outstanding. These warrants are dilutive and were included in the diluted earnings per share.

 

In March and April 2022, the Company issued and sold Pre-Funded Warrants to purchase an aggregate of 3,692,276 shares of common stock at a nominal exercise price of $0.001 per share (see Note 3). During the nine months ended September 30, 2022, all of these warrants were exercised and therefore had no remaining dilutive effect.

 
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
Management and Director Compensation
 9 Months Ended
Sep. 30, 2022
Management And Director Compensation  
Management and Director Compensation

Note 9 – Management and Director Compensation

 

The Company paid its officers cash compensation totaling $595,000 and $105,000 and $1,095,000 and $130,000 for the three and nine month periods ended September 30, 2022 and 2021, respectively. Of these amounts attributable to the Company’s CEO, as of September 30, 2021 $110,000 was paid to Advanomics Corporation, a company controlled by the CEO of the Company. In addition, the Company issued 300,000 shares of common stock valued at $918,000 to its officers during the three months ended September 30, 2021. The value of these shares was based upon the closing price of the Company’s common stock of $3.06 on the issuance date.

 

The Company paid its directors cash compensation totaling $100,000 and $200,000 for the three and nine month periods ended September 30, 2022 and 2021, respectively.

 
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Subsequent Events
 9 Months Ended
Sep. 30, 2022
Subsequent Events [Abstract]  
Subsequent Events

Note 10 – Subsequent Events

 

On October 20, 2022, the Company acquired all of the outstanding shares of Nora Pharma Inc., a Canadian generic pharmaceuticals company. The total purchase price of $30,000,000 Canadian (approximately $21,900,000 USD) was paid by paying $20,000,000 Canadian (approximately $14,600,000 USD) in cash, issuing 3,700,000 shares of the Company’s Common Stock valued at $5,000,000 Canadian (approximately $3,650,000 USD), and $5,000,000 Canadian (approximately $3,650,000 USD) which may be paid in the future as an earn-out amount based on target sales. Through the contingent earn-out, the seller, Mr. Malek Chamoun, has the opportunity to earn up to $5,000,000 CAD (approximately $3,650,000 USD) in the form of twenty (20) payments of $250,000 CAD for every $1,000,000 CAD increase in gross sales above Nora Pharma’s June 30, 2022 gross sales, provided that his employment with the Company is not terminated pursuant to the Company’s Employment Agreement with him.

 
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
Warrants (Tables)
 9 Months Ended
Sep. 30, 2022
Warrants  
Warrants issued with financing
     
TYPE NUMBER EXERCISE PRICE EXPIRY DATE
Pre-Funded Warrants 3,692,276 $0.001 Unlimited
Tradeable Warrants 4,102,200 $2.22* February 2027
Investor Warrants 3,603,604 $2.22 March 2027    
April Warrants 9,725,690 $3.76 April 2027

 

* The Tradeable Warrants had an initial exercise price of $4.25, subject to adjustment. Upon the closing of the Company’s private placement on March 14, 2022, the exercise price of the Tradeable Warrants was reduced to $2.22, in accordance with the terms thereof.
Schedule of outstanding warrants
     
TYPE NUMBER EXERCISE PRICE EXPIRY DATE
Pre-Funded Warrants None $0.001 Unlimited
Tradeable Warrants 963,693 $2.22 February 2027
Investor Warrants 800,901 $2.22 March 2027
April Warrants 9,725,690 $3.76 April 2027
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Nature of Business (Details Narrative) - USD ($)
 1 Months Ended
Mar. 14, 2022
Feb. 22, 2022
Feb. 17, 2022
Apr. 28, 2022
Feb. 28, 2022
Sep. 30, 2022
Securities Financing Transaction [Line Items]            
Stock Redeemed or Called During Period, Shares   990,000        
Warrant [Member]            
Securities Financing Transaction [Line Items]            
Class of Warrant or Right, Exercise Price of Warrants or Rights       $ 3.76    
Tradeable Warrants [Member]            
Securities Financing Transaction [Line Items]            
Class of Warrant or Right, Exercise Price of Warrants or Rights [1]           $ 2.22
Pre Funded Warrants [Member]            
Securities Financing Transaction [Line Items]            
Class of Warrant or Right, Exercise Price of Warrants or Rights           $ 0.001
Aegis Offering [Member]            
Securities Financing Transaction [Line Items]            
Proceeds from Issuance or Sale of Equity     $ 6,833,071      
Aegis Offering [Member] | Common Stock [Member]            
Securities Financing Transaction [Line Items]            
Stock Issued During Period, Shares, New Issues     1,882,353      
Aegis Offering [Member] | Tradeable Warrants [Member]            
Securities Financing Transaction [Line Items]            
Warrants issued new, shares     4,102,200   4,102,200  
Private Placement [Member]            
Securities Financing Transaction [Line Items]            
Proceeds from Issuance or Sale of Equity $ 6,781,199          
Proceeds from Issuance of Private Placement       $ 16,752,915    
Private Placement [Member] | Common Stock [Member]            
Securities Financing Transaction [Line Items]            
Stock Issued During Period, Shares, New Issues 2,301,353     2,472,820    
Private Placement [Member] | Investor Warrants 1 [Member]            
Securities Financing Transaction [Line Items]            
Warrants issued new, shares 2,301,353          
Private Placement [Member] | Pre Funded Warrants [Member]            
Securities Financing Transaction [Line Items]            
Warrants issued new, shares 1,302,251          
Private Placement [Member] | Investor Warrants 2 [Member]            
Securities Financing Transaction [Line Items]            
Warrants issued new, shares       4,945,640    
Private Placement [Member] | Pre Funded Warrants 1 [Member]            
Securities Financing Transaction [Line Items]            
Warrants issued new, shares       2,390,025    
[1] The Tradeable Warrants had an initial exercise price of $4.25, subject to adjustment. Upon the closing of the Company’s private placement on March 14, 2022, the exercise price of the Tradeable Warrants was reduced to $2.22, in accordance with the terms thereof.
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Reverse Stock Splits (Details Narrative)
Feb. 09, 2022
Apr. 06, 2020
Feb. 01, 2019
First Reverse Stock Split [Member]      
Offsetting Assets [Line Items]      
Stockholders' Equity, Reverse Stock Split     20 to 1 reverse split
Second Reverse Stock Split [Member]      
Offsetting Assets [Line Items]      
Stockholders' Equity, Reverse Stock Split   20 to 1 reverse split  
Third Reverse Stock Split [Member]      
Offsetting Assets [Line Items]      
Stockholders' Equity, Reverse Stock Split 1 for 200 reverse split    
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Notes Payable (Details Narrative) - USD ($)
 9 Months Ended
Feb. 17, 2022
Aug. 18, 2021
Jul. 06, 2021
Apr. 20, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Debt Instrument [Line Items]              
Notes Payable         $ 0   $ 1,900,000
Interest Payable         0   $ 48,287
Repayments of notes payable         $ 1,900,000 $ 451,661  
Note Payable 20211 [Member]              
Debt Instrument [Line Items]              
Face Value       $ 500,000      
Interest Rate       5.00%      
Maturity Date       Apr. 20, 2023      
Interest Paid, Including Capitalized Interest, Operating and Investing Activities $ 20,753            
Repayments of notes payable 520,753            
Note Payable 20212 [Member]              
Debt Instrument [Line Items]              
Face Value     $ 900,000        
Interest Rate     5.00%        
Maturity Date     Jul. 06, 2023        
Interest Paid, Including Capitalized Interest, Operating and Investing Activities 27,863            
Repayments of notes payable 927,863            
Note Payable 20213 [Member]              
Debt Instrument [Line Items]              
Face Value   $ 500,000          
Interest Rate   5.00%          
Maturity Date   Aug. 18, 2023          
Interest Paid, Including Capitalized Interest, Operating and Investing Activities 12,534            
Repayments of notes payable $ 512,534            
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Shareholders’ Equity (Details Narrative) - USD ($)
 1 Months Ended 9 Months Ended
Mar. 14, 2022
Feb. 22, 2022
Apr. 28, 2022
Apr. 22, 2022
Feb. 22, 2022
Feb. 17, 2022
Sep. 30, 2022
Class of Stock [Line Items]              
Proceeds from Issuance Initial Public Offering           $ 6,833,071  
Redeemed shares   990,000          
Dividends             $ 0
Warrant [Member]              
Class of Stock [Line Items]              
Warrants exercise price     $ 3.76        
Private Placement [Member]              
Class of Stock [Line Items]              
Proceeds from Issuance or Sale of Equity $ 6,781,199            
Proceeds from Issuance of private placement     $ 16,752,915        
Series B Preferred Stock [Member]              
Class of Stock [Line Items]              
Redeemed shares         990,000    
Redemption price   $ 0.10     $ 0.10    
Investor Warrants [Member]              
Class of Stock [Line Items]              
Warrants exercise price             $ 2.22
Investor Warrants [Member] | Private Placement [Member]              
Class of Stock [Line Items]              
Stock Issued During Period, Shares, New Issues 2,301,353            
Warrants issued new, shares       3,603,604      
Pre Funded Warrants [Member]              
Class of Stock [Line Items]              
Warrants exercise price             $ 0.001
Pre Funded Warrants [Member] | Private Placement [Member]              
Class of Stock [Line Items]              
Warrants issued new, shares 1,302,251            
Common Stock [Member] | Private Placement [Member]              
Class of Stock [Line Items]              
Stock Issued During Period, Shares, New Issues 2,301,353   2,472,820        
Investor Warrants 2 [Member] | Private Placement [Member]              
Class of Stock [Line Items]              
Warrants issued new, shares     4,945,640        
Pre Funded Warrants 1 [Member] | Private Placement [Member]              
Class of Stock [Line Items]              
Warrants issued new, shares     2,390,025        
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Warrants (Details)
 9 Months Ended
Sep. 30, 2022
$ / shares
shares
Pre Funded Warrants [Member]  
Number of shares | shares 3,692,276
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 0.001
Warrant Expiration Date Unlimited
Tradeable Warrants [Member]  
Number of shares | shares 4,102,200
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 2.22 [1]
Warrant Expiration Date February 2027
Investor Warrants [Member]  
Number of shares | shares 3,603,604
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 2.22
Warrant Expiration Date March 2027
April Warrants [Member]  
Number of shares | shares 9,725,690
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 3.76
Warrant Expiration Date April 2027
[1] The Tradeable Warrants had an initial exercise price of $4.25, subject to adjustment. Upon the closing of the Company’s private placement on March 14, 2022, the exercise price of the Tradeable Warrants was reduced to $2.22, in accordance with the terms thereof.
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Warrants (Details 1)
 9 Months Ended
Sep. 30, 2022
$ / shares
shares
Pre Funded Warrants [Member]  
Class of Warrant or Right, Exercise Price of Warrants or Rights $ 0.001
Warrant Expiration Date Unlimited
Tradeable Warrants [Member]  
Class of Warrant or Right, Exercise Price of Warrants or Rights $ 2.22 [1]
Warrant Expiration Date February 2027
Class of Warrant or Right, Outstanding | shares 963,693
Investor Warrants [Member]  
Class of Warrant or Right, Exercise Price of Warrants or Rights $ 2.22
Warrant Expiration Date March 2027
Class of Warrant or Right, Outstanding | shares 800,901
April Warrants [Member]  
Class of Warrant or Right, Exercise Price of Warrants or Rights $ 3.76
Warrant Expiration Date April 2027
Class of Warrant or Right, Outstanding | shares 9,725,690
[1] The Tradeable Warrants had an initial exercise price of $4.25, subject to adjustment. Upon the closing of the Company’s private placement on March 14, 2022, the exercise price of the Tradeable Warrants was reduced to $2.22, in accordance with the terms thereof.
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Warrants (Details Narrative)
 9 Months Ended
Sep. 30, 2022
USD ($)
shares
Tradeable Warrants [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised | shares 3,138,507
Proceeds from Warrant Exercises | $ $ 6,971,178
Investor Warrants [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised | shares 2,802,703
Investor Warrants And April Warrants [Member]  
Proceeds from Warrant Exercises | $ $ 6,222,001
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net Loss Per Common Share (Details Narrative) - shares
 1 Months Ended 9 Months Ended
Feb. 17, 2022
Apr. 22, 2022
Feb. 28, 2022
Sep. 30, 2022
Tradeable Warrants [Member]        
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]        
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised       3,138,507
Class of Warrant or Right, Outstanding       963,693
Investor Warrants [Member]        
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]        
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised       2,802,703
Class of Warrant or Right, Outstanding       800,901
April Warrants [Member]        
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]        
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised       0
Class of Warrant or Right, Outstanding       9,725,690
Aegis Offering [Member] | Tradeable Warrants [Member]        
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]        
[custom:WarrantsIssuedNewShares] 4,102,200   4,102,200  
Private Placement [Member] | Investor Warrants [Member]        
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]        
[custom:WarrantsIssuedNewShares]   3,603,604    
Private Placement [Member] | April Warrants [Member]        
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]        
[custom:WarrantsIssuedNewShares]   9,725,690    
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Management and Director Compensation (Details Narrative) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Defined Benefit Plan Disclosure [Line Items]        
Salary and Wage, Excluding Cost of Good and Service Sold $ 595,000 $ 105,000 $ 1,095,000 $ 130,000
Stock Issued During Period, Value, Issued for Services       918,000
Noninterest Expense Directors Fees $ 100,000 $ 200,000 100,000 $ 200,000
Advanomics Corporation [Member]        
Defined Benefit Plan Disclosure [Line Items]        
Salary and Wage, Excluding Cost of Good and Service Sold     $ 110,000  
Officers And Directors [Member]        
Defined Benefit Plan Disclosure [Line Items]        
Stock Issued During Period, Shares, Issued for Services   300,000    
Stock Issued During Period, Value, Issued for Services   $ 918,000    
XML 39 sunshine_i10q-093022_htm.xml IDEA: XBRL DOCUMENT 0001402328 2022-01-01 2022-09-30 0001402328 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001402328 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001402328 2022-11-07 0001402328 2022-09-30 0001402328 2021-12-31 0001402328 us-gaap:SeriesBPreferredStockMember 2022-09-30 0001402328 us-gaap:SeriesBPreferredStockMember 2021-12-31 0001402328 2022-07-01 2022-09-30 0001402328 2021-07-01 2021-09-30 0001402328 2021-01-01 2021-09-30 0001402328 2020-12-31 0001402328 2021-09-30 0001402328 us-gaap:CommonStockMember 2022-06-30 0001402328 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001402328 us-gaap:PreferredStockMember 2022-06-30 0001402328 us-gaap:ComprehensiveIncomeMember 2022-06-30 0001402328 us-gaap:RetainedEarningsMember 2022-06-30 0001402328 2022-06-30 0001402328 us-gaap:CommonStockMember 2021-12-31 0001402328 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001402328 us-gaap:PreferredStockMember 2021-12-31 0001402328 us-gaap:ComprehensiveIncomeMember 2021-12-31 0001402328 us-gaap:RetainedEarningsMember 2021-12-31 0001402328 us-gaap:CommonStockMember 2021-06-30 0001402328 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001402328 us-gaap:PreferredStockMember 2021-06-30 0001402328 us-gaap:ComprehensiveIncomeMember 2021-06-30 0001402328 us-gaap:RetainedEarningsMember 2021-06-30 0001402328 2021-06-30 0001402328 us-gaap:CommonStockMember 2020-12-31 0001402328 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001402328 us-gaap:PreferredStockMember 2020-12-31 0001402328 us-gaap:ComprehensiveIncomeMember 2020-12-31 0001402328 us-gaap:RetainedEarningsMember 2020-12-31 0001402328 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001402328 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001402328 us-gaap:PreferredStockMember 2022-07-01 2022-09-30 0001402328 us-gaap:ComprehensiveIncomeMember 2022-07-01 2022-09-30 0001402328 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001402328 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001402328 us-gaap:PreferredStockMember 2022-01-01 2022-09-30 0001402328 us-gaap:ComprehensiveIncomeMember 2022-01-01 2022-09-30 0001402328 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001402328 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001402328 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001402328 us-gaap:PreferredStockMember 2021-07-01 2021-09-30 0001402328 us-gaap:ComprehensiveIncomeMember 2021-07-01 2021-09-30 0001402328 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001402328 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001402328 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0001402328 us-gaap:PreferredStockMember 2021-01-01 2021-09-30 0001402328 us-gaap:ComprehensiveIncomeMember 2021-01-01 2021-09-30 0001402328 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0001402328 us-gaap:CommonStockMember 2022-09-30 0001402328 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001402328 us-gaap:PreferredStockMember 2022-09-30 0001402328 us-gaap:ComprehensiveIncomeMember 2022-09-30 0001402328 us-gaap:RetainedEarningsMember 2022-09-30 0001402328 us-gaap:CommonStockMember 2021-09-30 0001402328 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001402328 us-gaap:PreferredStockMember 2021-09-30 0001402328 us-gaap:ComprehensiveIncomeMember 2021-09-30 0001402328 us-gaap:RetainedEarningsMember 2021-09-30 0001402328 SBFM:AegisOfferingMember 2022-02-16 2022-02-17 0001402328 SBFM:AegisOfferingMember us-gaap:CommonStockMember 2022-02-16 2022-02-17 0001402328 SBFM:AegisOfferingMember SBFM:TradeableWarrantsMember 2022-02-16 2022-02-17 0001402328 2022-02-21 2022-02-22 0001402328 us-gaap:PrivatePlacementMember us-gaap:CommonStockMember 2022-03-13 2022-03-14 0001402328 us-gaap:PrivatePlacementMember SBFM:InvestorWarrants1Member 2022-03-13 2022-03-14 0001402328 us-gaap:PrivatePlacementMember SBFM:PreFundedWarrantsMember 2022-03-13 2022-03-14 0001402328 us-gaap:PrivatePlacementMember 2022-03-13 2022-03-14 0001402328 us-gaap:PrivatePlacementMember 2022-04-01 2022-04-28 0001402328 us-gaap:PrivatePlacementMember us-gaap:CommonStockMember 2022-04-01 2022-04-28 0001402328 us-gaap:PrivatePlacementMember SBFM:InvestorWarrants2Member 2022-04-01 2022-04-28 0001402328 us-gaap:PrivatePlacementMember SBFM:PreFundedWarrants1Member 2022-04-01 2022-04-28 0001402328 us-gaap:WarrantMember 2022-04-28 0001402328 SBFM:FirstReverseStockSplitMember 2019-01-31 2019-02-01 0001402328 SBFM:SecondReverseStockSplitMember 2020-04-05 2020-04-06 0001402328 SBFM:ThirdReverseStockSplitMember 2022-02-08 2022-02-09 0001402328 SBFM:NotePayable20211Member 2021-04-20 0001402328 SBFM:NotePayable20211Member 2021-04-19 2021-04-20 0001402328 SBFM:NotePayable20211Member 2022-02-16 2022-02-17 0001402328 SBFM:NotePayable20212Member 2021-07-06 0001402328 SBFM:NotePayable20212Member 2021-07-05 2021-07-06 0001402328 SBFM:NotePayable20212Member 2022-02-16 2022-02-17 0001402328 SBFM:NotePayable20213Member 2021-08-18 0001402328 SBFM:NotePayable20213Member 2021-08-17 2021-08-18 0001402328 SBFM:NotePayable20213Member 2022-02-16 2022-02-17 0001402328 2022-02-01 2022-02-17 0001402328 us-gaap:SeriesBPreferredStockMember 2022-02-01 2022-02-22 0001402328 us-gaap:SeriesBPreferredStockMember 2022-02-22 0001402328 us-gaap:PrivatePlacementMember SBFM:InvestorWarrantsMember 2022-03-13 2022-03-14 0001402328 SBFM:PreFundedWarrantsMember 2022-01-01 2022-09-30 0001402328 SBFM:PreFundedWarrantsMember 2022-09-30 0001402328 SBFM:TradeableWarrantsMember 2022-01-01 2022-09-30 0001402328 SBFM:TradeableWarrantsMember 2022-09-30 0001402328 SBFM:InvestorWarrantsMember 2022-01-01 2022-09-30 0001402328 SBFM:InvestorWarrantsMember 2022-09-30 0001402328 SBFM:AprilWarrantsMember 2022-01-01 2022-09-30 0001402328 SBFM:AprilWarrantsMember 2022-09-30 0001402328 SBFM:InvestorWarrantsAndAprilWarrantsMember 2022-01-01 2022-09-30 0001402328 SBFM:AegisOfferingMember SBFM:TradeableWarrantsMember 2022-02-01 2022-02-28 0001402328 us-gaap:PrivatePlacementMember SBFM:InvestorWarrantsMember 2022-04-01 2022-04-22 0001402328 us-gaap:PrivatePlacementMember SBFM:AprilWarrantsMember 2022-04-01 2022-04-22 0001402328 SBFM:AdvanomicsCorporationMember 2022-01-01 2022-09-30 0001402328 SBFM:OfficersAndDirectorsMember 2021-07-01 2021-09-30 iso4217:USD shares iso4217:USD shares pure 0001402328 false --12-31 2022 Q3 10-Q true 2022-09-30 false 001-41282 SUNSHINE BIOPHARMA, INC. CO 20-5566275 6500 Trans-Canada Highway 4th Floor Pointe-Claire Quebec CA H9R 0A5 (514) 426-6161 Common Stock Common Stock Purchase Warrants SBFM SBFMW NASDAQ NASDAQ Yes Yes Non-accelerated Filer true false false 22585632 40555931 2045167 22 7798 269641 105650 27390 29625 7590 7590 40860574 2195830 3770 7061 40864344 2202891 480209 42942 0 48287 480209 91229 0 1900000 480209 1991229 0.10 0.10 1000000 1000000 10000 10000 1000000 1000000 1000 100000 0.001 0.001 3000000000 3000000000 18885632 18885632 2591240 2591240 18886 2591 76331451 32787384 -79903 -23139 -35887299 -32655174 40384135 211662 40864344 2202891 132808 50376 405760 143308 65783 19506 200311 56541 67025 30870 205449 86767 122913 35000 237773 96200 217666 0 400386 0 162852 20598 270033 53168 142883 56923 388238 159074 76818 58959 449730 159762 695000 130000 1305000 1173927 3584 1 15148 14571 362500 222465 770095 581011 789 3183 6186 9557 1785005 527129 3842589 2247270 -1717980 -496259 -3637140 -2160503 25 37 45 31 260938 0 406984 0 2 46849 12866 292188 0 7688 10852 58940 -0 3504000 -0 10709843 260961 -3543124 405015 -10943060 -1457019 -4039383 -3232125 -13103563 -0 -0 -0 -0 -1457019 -4039383 -3232125 -13103563 -45126 -5839 -56764 -14604 -1502145 -4045222 -3288889 -13118167 -0.08 -1.59 -0.26 -5.73 18885632 2542640 12789733 2287682 -3232125 -13103563 6186 9557 -45 31 0 918000 0 38201 0 10709843 10852 58940 -7776 -787 163991 47539 -2235 22268 437267 -13778 -48287 52716 -3001746 -1517015 -43560363 -3318500 -99000 61500 1900000 451661 41561363 2928339 2045167 989888 38559617 1411324 -105617 0 56764 -14604 40555931 2386608 0 11981072 61151 155081 0 0 18885632 18886 76331451 10000 1000 -34777 -34430280 41886280 -45126 -1457019 -1502145 18885632 18886 76331451 10000 1000 -79903 -35887299 40384135 2595620 2596 32787379 1000000 100000 -23139 -32655174 211662 6656526 6657 30360528 30367185 9633486 9633 13183544 13193177 -990000 99000 99000 -56764 -3232125 -3288889 18885632 18886 76331451 10000 1000 -79903 -35887299 40384135 2430466 2430 28319403 1000000 100000 -11636 -29282907 -872710 120000 120 3743880 3744000 -5839 -4039383 -4045222 2550466 2550 32063283 1000000 100000 -17475 -33322290 -1173932 1732096 1732 19165029 1000000 100000 -2871 -20218727 -954837 518370 518 11980554 11981072 300000 300 917700 918000 -14604 -13103563 -13118167 2550466 2550 32063283 1000000 100000 -17475 -33322290 -1173932 <p id="xdx_80C_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zRCGoJciIFsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><b><span style="text-decoration: underline">Note 1 – <span id="xdx_82F_zlHf7ZY6nuQj">Nature of Business</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Sunshine Biopharma, Inc. (the “Company”) was originally incorporated under the name Mountain West Business Solutions, Inc. on August 31, 2006, in the State of Colorado. Until October 2009, the Company was operating as a business consultancy firm.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Effective October 15, 2009, the Company acquired Sunshine Biopharma, Inc. in a transaction classified as a reverse acquisition. Sunshine Biopharma, Inc. held an exclusive license to a new anticancer drug bearing the laboratory name, Adva-27a (the “License Agreement”). Upon completion of the reverse acquisition transaction, the Company changed its name to Sunshine Biopharma, Inc. and began operating as a pharmaceutical company focusing on the development of the licensed Adva-27a anticancer drug.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">In December 2015, the Company acquired all issued (US Patent Number 8,236,935, and 10,272,065) and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029 for the Adva-27a anticancer compound from Advanomics Corporation, a related party, and terminated the License Agreement. In 2016, the remaining value of these patents was impaired. The Company is however continuing development of the Adva-27a anticancer drug covered by these patents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">In December 2018, the Company launched a Science-Based Nutritional Supplements product, Essential 9<span style="font-variant: small-caps"><sup>™</sup></span>, an over-the-counter capsule comprised of the nine (9) essential amino acids that the human body cannot make. Essential 9<span style="font-variant: small-caps"><sup>™ </sup></span>has been authorized for marketing by Health Canada under NPN 80089663.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On May 22, 2020, the Company filed a provisional patent application in the United States for a new treatment for Coronavirus infections. The Company’s patent application covers composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease, Mpro, an enzyme that is essential for viral replication. The patent application has a priority date of May 22, 2020. On April 30, 2021, the Company filed a PCT application containing new research results and extending coverage to include the Coronavirus Papain-Like protease, PLpro. The priority date of May 22, 2020 has been maintained in the newly filed PCT application. The Company’s lead Anti-Coronavirus compound arising from these patents bears the laboratory name SBFM-PL4.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On January 26, 2021, the Company received a Notice of Allowances from the Canadian Intellectual Property Office for a new patent application covering Adva-27a. The newly issued patent contains new subject matter and extends the proprietary protection of Adva-27a in Canada until 2033.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On March 9, 2021, the Company received a Notice of Allowance from the European Patent Office for a new patent application covering Adva-27a. The newly issued patent contains new subject matter and extends the proprietary protection of Adva-27a in Europe until 2033. The equivalent patent in the United States was issued in 2019 (US Patent Number 10,272,065).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On February 15, 2022, the Company entered into an underwriting agreement with Aegis Capital Corp. as underwriter, for the issuance and sale in an underwritten public offering of 1,882,353 Units, each consisting of one share of common stock and two warrants (“Tradeable Warrants”) to purchase shares of common stock at a public offering price of $4.25 per Unit for total gross proceeds of $8,000,000 (“Public Offering”). On February 17, 2022, the Public Offering closed and the Company received net proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20220216__20220217__us-gaap--SecuritiesFinancingTransactionAxis__custom--AegisOfferingMember_pp0p0" title="Proceeds from Issuance or Sale of Equity">6,833,071</span>. Pursuant to the Public Offering, the Company issued and sold an aggregate of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220216__20220217__us-gaap--SecuritiesFinancingTransactionAxis__custom--AegisOfferingMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_pdd" title="Stock Issued During Period, Shares, New Issues">1,882,353</span> shares of common stock and <span id="xdx_901_ecustom--WarrantsIssuedNewShares_c20220216__20220217__us-gaap--SecuritiesFinancingTransactionAxis__custom--AegisOfferingMember__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_pdd" title="Warrants issued new, shares">4,102,200</span> Tradeable Warrants (including 337,494 Tradeable Warrants purchased at $0.01 per warrant resulting from partial exercise of the overallotment option granted to the underwriter). In connection with these transactions, the Company’s shares of common stock and Tradeable Warrants began trading on Nasdaq under the symbol “SBFM” for the common stock and “SBFMW” for the Tradeable Warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On February 18, 2022, the Company entered into a research agreement (the “SRA”) with the University of Arizona for the purposes of conducting research focused on determining the in vivo safety, pharmacokinetics, and dose selection properties of three University of Arizona owned PLpro inhibitors, to be followed by efficacy testing in mice infected with SARS-CoV-2 (the “Research Project”). Under the SRA, the University of Arizona granted the Company a first option to negotiate a commercial, royalty-bearing license for all intellectual property developed by University of Arizona personnel under the Research Project. In addition, the Company and the University of Arizona entered into an Option Agreement whereby the Company was granted a first option to negotiate a royalty-bearing commercial license for the underlying technology of the Research Project. Intending to move forward with the technology, the Company submitted a Notice of Option Exercise to the University of Arizona on September 13, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On February 22, 2022, the Company redeemed <span id="xdx_90F_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20220221__20220222_pdd" title="Stock Redeemed or Called During Period, Shares">990,000</span> shares of the Series B Preferred Stock from the CEO of the Company at a redemption price equal to the stated value of $0.10 per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On March 14, 2022, the Company completed a private placement wherein the Company sold (i) <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220313__20220314__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_pdd">2,301,353</span></span><span style="background-color: white"> shares of its common stock together with warrants (the “Investor Warrants”) to purchase up to<span id="xdx_908_ecustom--WarrantsIssuedNewShares_c20220313__20220314__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrants1Member_pdd"> 2,301,353 </span></span><span style="background-color: white">shares of common stock, and (ii) <span id="xdx_90F_ecustom--WarrantsIssuedNewShares_c20220313__20220314__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_pdd">1,302,251</span></span><span style="background-color: white"> pre-funded warrants (“Pre-Funded Warrants”) with each Pre-Funded Warrant exercisable for one share of common stock, together with Investor Warrants to purchase up to 1,302,251 shares of common stock. Each share of common stock and accompanying Investor Warrant were sold together at a combined offering price of $2.22, and each Pre-Funded Warrant and accompanying Investor Warrant were sold together at a combined offering price of $2.219. The Company received approximately $8 million in gross proceeds, and $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20220313__20220314__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember_pp0p0">6,781,199</span></span><span style="background-color: white"> in net proceeds in this offering.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On April 28, 2022, the Company completed another private placement and received net proceeds of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20220401__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember_pp0p0">16,752,915</span></span><span style="background-color: white">. In connection with this private placement, the Company issued (i) <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220401__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_pdd">2,472,820</span></span><span style="background-color: white"> shares of its common stock together with warrants (“April Warrants”) to purchase up to <span id="xdx_900_ecustom--WarrantsIssuedNewShares_c20220401__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrants2Member_pdd">4,945,640 </span></span><span style="background-color: white">shares of common stock, and (ii) <span id="xdx_904_ecustom--WarrantsIssuedNewShares_c20220401__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants1Member_pdd">2,390,025 </span></span><span style="background-color: white">pre-funded warrants (“Pre-Funded Warrants”) with each Pre-Funded Warrant exercisable for one share of common stock, together with April Warrants to purchase up to 4,780,050 shares of common stock. Each share of common stock and accompanying two April Warrants were sold together at a combined offering price of $4.01, and each Pre-Funded Warrant and accompanying two April Warrants were sold together at a combined offering price of $4.01, and each Pre-Funded Warrant and accompanying two April Warrants were sold together at a combined offering price of $4.009. The Pre-Funded Warrants were immediately exercisable, at a nominal exercise price of $0.001, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The April Warrants have an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220428__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd">3.76 </span></span><span style="background-color: white">per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance and will expire five years from the date of issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 20, 2022, the Company acquired Nora Pharma Inc. (“Nora Pharma”), a Canadian generic pharmaceuticals company. Based in the greater Montreal area, Nora Pharma has 36 employees and operates in a 15,000 square foot facility certified by Health Canada. Nora Pharma currently offers over 50 pharmaceutical products, including generic prescription drugs, over-the-counter products and biosimilars. Nora Pharma sales were $10.7 million (USD) during its fiscal year ended June 30, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 6833071 1882353 4102200 990000 2301353 2301353 1302251 6781199 16752915 2472820 4945640 2390025 3.76 <p id="xdx_802_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zGEGakfpMLhd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><b><span style="text-decoration: underline">Note 2 – <span id="xdx_822_zczBcFMrN9ie">Basis of Presentation</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><span style="background-color: white">The unaudited financial statements of the Company for the nine month periods ended September 30, 2022 and 2021 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Regulation S-X. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. However, such information reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year. The balance sheet information as of December 31, 2021 was derived from the audited financial statements included in the Company's financial statements as of and for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 21, 2022. These financial statements should be read in conjunction with that report.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_80E_ecustom--ImpactOfCovid19PandemicTextBlock_zZYpGK7MXGG6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><b><span style="text-decoration: underline">Note 3 – <span id="xdx_825_zVeUWF3B06Si">Impact of Coronavirus (COVID-19) Pandemic</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">In March 2020, the World Health Organization declared Coronavirus and its associated disease, COVID-19, a global pandemic. Conditions surrounding the Coronavirus outbreak have been and are continuing to evolve rapidly. Government authorities in the U.S. and around the world have implemented emergency measures to mitigate the spread of the virus. The outbreak and related mitigation measures have had and will continue to have a material adverse impact on the world economies and the Company's business activities. It is not possible for the Company to predict the duration or magnitude of the adverse conditions of the outbreak and their effects on the Company’s business or ability to raise funds. No adjustments have been made to the amounts reported in the Company's financial statements as a result of this matter.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_80B_ecustom--ReverseStockSplitTextBlock_ztPbEHMkQjse" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white"><b><span style="text-decoration: underline">Note 4 – <span id="xdx_82C_zAUwOLjgxFqg">Reverse Stock Splits</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Effective February 1, 2019, the Company completed a <span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20190131__20190201__us-gaap--TransactionTypeAxis__custom--FirstReverseStockSplitMember" title="Stockholders' Equity, Reverse Stock Split">20 to 1 reverse split</span> of its common stock (the “First Reverse Stock Split”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Effective April 6, 2020, the Company completed another <span id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20200405__20200406__us-gaap--TransactionTypeAxis__custom--SecondReverseStockSplitMember" title="Stockholders' Equity, Reverse Stock Split">20 to 1 reverse split</span> of its common stock (the “Second Reverse Stock Split”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Effective February 9, 2022, the Company completed a <span id="xdx_903_eus-gaap--StockholdersEquityReverseStockSplit_c20220208__20220209__us-gaap--TransactionTypeAxis__custom--ThirdReverseStockSplitMember" title="Stockholders' Equity, Reverse Stock Split">1 for 200 reverse split</span> of its common stock (the “Third Reverse Stock Split”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Company's financial statements reflect the First, Second, and Third Reverse Stock Split on a retroactive basis for all periods presented and for all references to common stock, unless specifically stated otherwise.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 20 to 1 reverse split 20 to 1 reverse split 1 for 200 reverse split <p id="xdx_80A_eus-gaap--DebtDisclosureTextBlock_zIjY918A1zx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><b><span style="text-decoration: underline">Note 5 – <span id="xdx_823_zHdkBo7f74Tb">Notes Payable</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">As of September 30, 2022 and December 31, 2021, the Company had $<span id="xdx_906_eus-gaap--NotesPayable_c20220930_pp0p0" title="Notes Payable">0</span> and $<span id="xdx_90D_eus-gaap--NotesPayable_c20211231_pp0p0" title="Notes Payable">1,900,000</span>, respectively in notes payable outstanding. At September 30, 2022 and December 31, 2021, total accrued interest on Notes Payable was $<span id="xdx_90F_eus-gaap--InterestPayableCurrentAndNoncurrent_c20220930_pp0p0" title="Interest Payable">0</span> and $<span id="xdx_905_eus-gaap--InterestPayableCurrentAndNoncurrent_c20211231_pp0p0" title="Interest Payable">48,287</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Company’s Notes Payable at December 31, 2021 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On April 20, 2021, the Company received monies in exchange for a Note Payable having a Face Value of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_c20210420__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20211Member_pp0p0">500,000 </span></span><span style="background-color: white">with interest accruing at <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210419__20210420__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20211Member_zfUehJhVlDTd">5</span></span><span style="background-color: white">% due <span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20210419__20210420__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20211Member_zoXFSsErNVG3">April 20, 2023</span></span><span style="background-color: white">. The Note was convertible after 180 days from issuance into common stock at a price equal to $0.30 per share. On February 17, 2022, the Company paid off the entire principal balance of this Note, together with accrued interest of $<span id="xdx_90C_eus-gaap--InterestPaid_c20220216__20220217__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20211Member_pp0p0">20,753 </span></span><span style="background-color: white">by making cash payment of $<span id="xdx_903_eus-gaap--RepaymentsOfNotesPayable_c20220216__20220217__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20211Member_pp0p0">520,753</span></span><span style="background-color: white">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On July 6, 2021, the Company received monies in exchange for a Note Payable having a Face Value of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_c20210706__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20212Member_pp0p0" title="Face Value">900,000</span> with interest accruing at <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210705__20210706__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20212Member_z5qQ2wwD9vwf" title="Interest Rate">5</span>%, due <span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20210705__20210706__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20212Member_zNGq6LHFQq45" title="Maturity Date">July 6, 2023</span>. The Note was convertible after 180 days from issuance into common stock at a price equal to $0.30 per share. On February 17, 2022, the Company paid off the entire principal balance of this Note, together with accrued interest of $<span id="xdx_90F_eus-gaap--InterestPaid_c20220216__20220217__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20212Member_pp0p0" title="Interest Paid, Including Capitalized Interest, Operating and Investing Activities">27,863</span> by making cash payment of $<span id="xdx_900_eus-gaap--RepaymentsOfNotesPayable_c20220216__20220217__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20212Member_pp0p0" title="Repayments of notes payable">927,863</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On August 18, 2021, the Company received monies in exchange for a Note Payable having a Face Value of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_c20210818__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20213Member_pp0p0" title="Face Value">500,000</span> with interest accruing at <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210817__20210818__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20213Member_zKf9wfpthzJg" title="Interest Rate">5</span>%, due <span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_dd_c20210817__20210818__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20213Member_zAwrfhewIfW1" title="Maturity Date">August 18, 2023</span>. The Note was convertible after 180 days from issuance into common stock at a price equal to $0.30 per share. On February 17, 2022, the Company paid off the entire principal balance of this Note, together with accrued of $<span id="xdx_90E_eus-gaap--InterestPaid_c20220216__20220217__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20213Member_pp0p0" title="Interest Paid, Including Capitalized Interest, Operating and Investing Activities">12,534</span> by making cash payment of $<span id="xdx_901_eus-gaap--RepaymentsOfNotesPayable_c20220216__20220217__us-gaap--LongtermDebtTypeAxis__custom--NotePayable20213Member_pp0p0" title="Repayments of notes payable">512,534</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 0 1900000 0 48287 500000 0.05 2023-04-20 20753 520753 900000 0.05 2023-07-06 27863 927863 500000 0.05 2023-08-18 12534 512534 <p id="xdx_802_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zfxYG5deiIkg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><b><span style="text-decoration: underline">Note 6 – <span id="xdx_829_za3LzhL5ZCWc">Shareholders’ Equity</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On February 17, 2022, the Company’s Public Offering closed and the Company received net proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20220201__20220217_pp0p0">6,833,071 </span></span><span style="background-color: white">from the offering. Pursuant to the Public Offering, the Company issued and sold an aggregate of 1,882,353 shares of common stock and 4,102,200 Tradeable Warrants (including 337,494 Tradeable Warrants resulting from partial exercise of the overallotment option granted to the underwriter).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On February 22, 2022, the Company redeemed <span id="xdx_90C_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20220201__20220222__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Redeemed shares">990,000</span> shares of Series B Preferred Stock from the CEO of the Company at a redemption price equal to the stated value of $<span id="xdx_90A_eus-gaap--PreferredStockRedemptionPricePerShare_c20220222__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Redemption price">0.10</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On March 14, 2022, the Company completed a private placement and received net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20220313__20220314__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember_z7RxScqpDXvl" title="Proceeds from Issuance or Sale of Equity">6,781,199</span>. In connection with this private placement, the Company issued (i)<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220313__20220314__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_pdd" title="Stock Issued During Period, Shares, New Issues"> 2,301,353</span> shares of its common stock together with investor warrants (“Investor Warrants”) to purchase up to 2,301,353 shares of common stock, and (ii) <span id="xdx_901_ecustom--WarrantsIssuedNewShares_c20220313__20220314__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_zcUH3BK5iNh1" title="Warrants issued new, shares">1,302,251</span> pre-funded warrants (“Pre-Funded Warrants”) with each Pre-Funded Warrant exercisable for one share of common stock, together with Investor Warrants to purchase up to 1,302,251 shares of common stock. Each share of common stock and accompanying Investor Warrant were sold together at a combined offering price of $2.22 and each Pre-Funded Warrant and accompanying Investor Warrant were sold together at a combined offering price of $2.219. The Pre-Funded Warrants were immediately exercisable, at a nominal exercise price of $0.001, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Investor Warrants have an exercise price of $2.22 per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance and will expire five years from the date of issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">On April 28, 2022, the Company completed another private placement and received net proceeds of $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pp0p0_c20220401__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember_zrRNB51zloHk" title="Proceeds from Issuance of private placement">16,752,915</span>. In connection with this private placement, the Company issued (i) <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220401__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zVRLLIrEZlz2" title="Stock Issued During Period, Shares, New Issues">2,472,820</span> shares of its common stock together with warrants (“April Warrants”) to purchase up to <span id="xdx_905_ecustom--WarrantsIssuedNewShares_c20220401__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrants2Member_zHmgd9Codlqa" title="Warrants issued new, shares">4,945,640</span> shares of common stock, and (ii) <span id="xdx_902_ecustom--WarrantsIssuedNewShares_c20220401__20220428__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrants1Member_zEIK3hdBv2pi" title="Warrants issued new, shares">2,390,025</span> pre-funded warrants (“Pre-Funded Warrants”) with each Pre-Funded Warrant exercisable for one share of common stock, together with April Warrants to purchase up to 4,780,050 shares of common stock. Each share of common stock and accompanying two April Warrants were sold together at a combined offering price of $4.01 and each Pre-Funded Warrant and accompanying two April Warrants were sold together at a combined offering price of $4.009. The Pre-Funded Warrants were immediately exercisable, at a nominal exercise price of $0.001, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The April Warrants have an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220428__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zmq8UzUUloNg" title="Warrants exercise price">3.76</span> per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance and will expire five years from the date of issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Company declared <span id="xdx_901_eus-gaap--Dividends_pp0p0_do_c20220101__20220930_zXwikgkfLBi7" title="Dividends">no</span> dividends through September 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> 6833071 990000 0.10 6781199 2301353 1302251 16752915 2472820 4945640 2390025 3.76 0 <p id="xdx_800_ecustom--WarrantsDisclosureTextBlock_z2EZ1eQYoJf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white"><b><span style="text-decoration: underline">Note 7 – <span id="xdx_829_zJOGzDDhVmPl">Warrants</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 2.5pt 0 0; text-align: justify"><span style="background-color: white">The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10 or ASC 815-40. Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 2.6pt 0 0; text-align: justify"><span style="background-color: white">During the nine months ended September 30, 2022, the Company completed three financing events, and in connection therewith, it issued warrants as follows: </span></p> <table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--WarrantsIssuedWithFinancingTableTextBlock_zto3YGMcO6i8" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Warrants (Details)"> <tr style="background-color: white"> <td style="vertical-align: top"><span id="xdx_8B0_z6ZkAZ3xHys" style="display: none">Warrants issued with financing</span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td></tr> <tr style="vertical-align: top"> <td style="border-bottom: black 1pt solid; width: 31%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TYPE</b></span></td> <td style="border-bottom: black 1pt solid; width: 23%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NUMBER</b></span></td> <td style="border-bottom: black 1pt solid; width: 22%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXERCISE PRICE</b></span></td> <td style="border-bottom: black 1pt solid; width: 24%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXPIRY DATE</b></span></td></tr> <tr style="background-color: #EEEEEE"> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Funded Warrants</span></td> <td id="xdx_983_ecustom--WarrantsIssuedShares_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_pdd" style="vertical-align: top" title="Number of shares"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,692,276</span></td> <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220930__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_zio0vAHNntT" style="vertical-align: top" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.001</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--WarrantExpirationDate_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_zHdx93BSi2t3" title="Warrant Expiration Date">Unlimited</span></span></td></tr> <tr style="background-color: white"> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tradeable Warrants</span></td> <td id="xdx_989_ecustom--WarrantsIssuedShares_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_pdd" style="vertical-align: top" title="Number of shares"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,102,200</span></td> <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220930__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_fKg_____zQGFrXaQW311" style="vertical-align: top" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.22*</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--WarrantExpirationDate_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_zXlUvEnrDI1i" title="Warrant Expiration Date">February 2027</span></span></td></tr> <tr style="background-color: #EEEEEE"> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor Warrants</span></td> <td id="xdx_988_ecustom--WarrantsIssuedShares_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_pdd" style="vertical-align: top" title="Number of shares"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,603,604</span></td> <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220930__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_z0HwipsABb34" style="vertical-align: top" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.22</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--WarrantExpirationDate_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_zcaEIr38aVAl" title="Warrant Expiration Date">March 2027</span>    </span></td></tr> <tr style="background-color: white"> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April Warrants</span></td> <td id="xdx_986_ecustom--WarrantsIssuedShares_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_pdd" style="vertical-align: top" title="Number of shares"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,725,690</span></td> <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220930__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_z2N6bJBgJaJh" style="vertical-align: top" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$3.76</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--WarrantExpirationDate_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_z1oqOHzR0b5i" title="Warrant Expiration Date">April 2027</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 1%"><span id="xdx_F0F_znibF7qViHI3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="text-align: justify; width: 99%"><span id="xdx_F13_zvP9TIosD3C2" style="font-family: Times New Roman, Times, Serif; font-size: 8pt">The Tradeable Warrants had an initial exercise price of $4.25, subject to adjustment. Upon the closing of the Company’s private placement on March 14, 2022, the exercise price of the Tradeable Warrants was reduced to $2.22, in accordance with the terms thereof.</span></td></tr> </table> <p id="xdx_8A0_zEZIKonG725c" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">During the nine months ended September 30, 2022, all of the Pre-Funded Warrants and a total of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_pdd">3,138,507</span></span><span style="background-color: white"> Tradeable Warrants were exercised resulting in aggregate proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromWarrantExercises_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_pp0p0">6,971,178</span></span><span style="background-color: white"> received by the Company. In addition, during the nine months ended September 30, 2022, a total of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_pdd">2,802,703</span></span><span style="background-color: white"> Investor Warrants were exercised resulting in aggregate proceeds of $<span id="xdx_90C_eus-gaap--ProceedsFromWarrantExercises_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsAndAprilWarrantsMember_pp0p0">6,222,001</span></span><span style="background-color: white"> received by the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white">The Company’s outstanding warrants at September 30, 2022 consisted of the following: </span></p> <table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zGWgHCYSaWt9" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Warrants (Details 1)"> <tr style="vertical-align: top; background-color: white"> <td><span id="xdx_8BC_zZXCpmRas6Ci" style="display: none">Schedule of outstanding warrants</span></td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top"> <td style="border-bottom: black 1pt solid; width: 31%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TYPE</b></span></td> <td style="border-bottom: black 1pt solid; width: 23%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NUMBER</b></span></td> <td style="border-bottom: black 1pt solid; width: 22%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXERCISE PRICE</b></span></td> <td style="border-bottom: black 1pt solid; width: 24%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXPIRY DATE</b></span></td></tr> <tr style="vertical-align: top; background-color: #EEEEEE"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Funded Warrants</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></td> <td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220930__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_zfSTOkhNrPc" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.001</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--WarrantExpirationDate_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_z6EALlKD9Xe7" title="Warrant Expiration Date">Unlimited</span></span></td></tr> <tr style="vertical-align: top; background-color: white"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tradeable Warrants</span></td> <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220930__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_pdd" title="Class of Warrant or Right, Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">963,693</span></td> <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220930__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_zoCVpkHA7mv3" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.22</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--WarrantExpirationDate_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_zJu77EyTaTrh" title="Warrant Expiration Date">February 2027</span></span></td></tr> <tr style="vertical-align: top; background-color: #EEEEEE"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor Warrants</span></td> <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220930__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_pdd" title="Class of Warrant or Right, Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">800,901</span></td> <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220930__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_zRjRo87iDkb1" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.22</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--WarrantExpirationDate_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_zvMKIfQ4izvi" title="Warrant Expiration Date">March 2027</span></span></td></tr> <tr style="vertical-align: top; background-color: white"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April Warrants</span></td> <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220930__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_pdd" title="Class of Warrant or Right, Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,725,690</span></td> <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220930__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_zWu4zgYw4Ucf" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$3.76</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--WarrantExpirationDate_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_zPWJUXQOtaY9" title="Warrant Expiration Date">April 2027</span></span></td></tr> </table> <p id="xdx_8AE_zYKSDxPjad7a" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--WarrantsIssuedWithFinancingTableTextBlock_zto3YGMcO6i8" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Warrants (Details)"> <tr style="background-color: white"> <td style="vertical-align: top"><span id="xdx_8B0_z6ZkAZ3xHys" style="display: none">Warrants issued with financing</span></td> <td style="vertical-align: top"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td></tr> <tr style="vertical-align: top"> <td style="border-bottom: black 1pt solid; width: 31%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TYPE</b></span></td> <td style="border-bottom: black 1pt solid; width: 23%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NUMBER</b></span></td> <td style="border-bottom: black 1pt solid; width: 22%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXERCISE PRICE</b></span></td> <td style="border-bottom: black 1pt solid; width: 24%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXPIRY DATE</b></span></td></tr> <tr style="background-color: #EEEEEE"> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Funded Warrants</span></td> <td id="xdx_983_ecustom--WarrantsIssuedShares_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_pdd" style="vertical-align: top" title="Number of shares"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,692,276</span></td> <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220930__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_zio0vAHNntT" style="vertical-align: top" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.001</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--WarrantExpirationDate_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_zHdx93BSi2t3" title="Warrant Expiration Date">Unlimited</span></span></td></tr> <tr style="background-color: white"> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tradeable Warrants</span></td> <td id="xdx_989_ecustom--WarrantsIssuedShares_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_pdd" style="vertical-align: top" title="Number of shares"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,102,200</span></td> <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220930__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_fKg_____zQGFrXaQW311" style="vertical-align: top" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.22*</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--WarrantExpirationDate_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_zXlUvEnrDI1i" title="Warrant Expiration Date">February 2027</span></span></td></tr> <tr style="background-color: #EEEEEE"> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor Warrants</span></td> <td id="xdx_988_ecustom--WarrantsIssuedShares_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_pdd" style="vertical-align: top" title="Number of shares"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,603,604</span></td> <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220930__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_z0HwipsABb34" style="vertical-align: top" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.22</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--WarrantExpirationDate_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_zcaEIr38aVAl" title="Warrant Expiration Date">March 2027</span>    </span></td></tr> <tr style="background-color: white"> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April Warrants</span></td> <td id="xdx_986_ecustom--WarrantsIssuedShares_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_pdd" style="vertical-align: top" title="Number of shares"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,725,690</span></td> <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220930__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_z2N6bJBgJaJh" style="vertical-align: top" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$3.76</span></td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--WarrantExpirationDate_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_z1oqOHzR0b5i" title="Warrant Expiration Date">April 2027</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 1%"><span id="xdx_F0F_znibF7qViHI3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="text-align: justify; width: 99%"><span id="xdx_F13_zvP9TIosD3C2" style="font-family: Times New Roman, Times, Serif; font-size: 8pt">The Tradeable Warrants had an initial exercise price of $4.25, subject to adjustment. Upon the closing of the Company’s private placement on March 14, 2022, the exercise price of the Tradeable Warrants was reduced to $2.22, in accordance with the terms thereof.</span></td></tr> </table> 3692276 0.001 Unlimited 4102200 2.22 February 2027 3603604 2.22 March 2027 9725690 3.76 April 2027 3138507 6971178 2802703 6222001 <table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zGWgHCYSaWt9" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Warrants (Details 1)"> <tr style="vertical-align: top; background-color: white"> <td><span id="xdx_8BC_zZXCpmRas6Ci" style="display: none">Schedule of outstanding warrants</span></td> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top"> <td style="border-bottom: black 1pt solid; width: 31%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TYPE</b></span></td> <td style="border-bottom: black 1pt solid; width: 23%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NUMBER</b></span></td> <td style="border-bottom: black 1pt solid; width: 22%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXERCISE PRICE</b></span></td> <td style="border-bottom: black 1pt solid; width: 24%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXPIRY DATE</b></span></td></tr> <tr style="vertical-align: top; background-color: #EEEEEE"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Funded Warrants</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></td> <td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220930__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_zfSTOkhNrPc" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.001</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--WarrantExpirationDate_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember_z6EALlKD9Xe7" title="Warrant Expiration Date">Unlimited</span></span></td></tr> <tr style="vertical-align: top; background-color: white"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tradeable Warrants</span></td> <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220930__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_pdd" title="Class of Warrant or Right, Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">963,693</span></td> <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220930__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_zoCVpkHA7mv3" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.22</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--WarrantExpirationDate_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_zJu77EyTaTrh" title="Warrant Expiration Date">February 2027</span></span></td></tr> <tr style="vertical-align: top; background-color: #EEEEEE"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor Warrants</span></td> <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220930__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_pdd" title="Class of Warrant or Right, Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">800,901</span></td> <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220930__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_zRjRo87iDkb1" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.22</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--WarrantExpirationDate_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_zvMKIfQ4izvi" title="Warrant Expiration Date">March 2027</span></span></td></tr> <tr style="vertical-align: top; background-color: white"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April Warrants</span></td> <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220930__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_pdd" title="Class of Warrant or Right, Outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,725,690</span></td> <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220930__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_zWu4zgYw4Ucf" title="Class of Warrant or Right, Exercise Price of Warrants or Rights"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$3.76</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--WarrantExpirationDate_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_zPWJUXQOtaY9" title="Warrant Expiration Date">April 2027</span></span></td></tr> </table> 0.001 Unlimited 963693 2.22 February 2027 800901 2.22 March 2027 9725690 3.76 April 2027 <p id="xdx_808_eus-gaap--EarningsPerShareTextBlock_ztdRvyK8XMjd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><b><span style="text-decoration: underline">Note 8 – <span id="xdx_822_zAySfkLCkaUa">Net Loss Per Common Share</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, taking into consideration common stock equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">In February 2022, the Company issued <span id="xdx_90D_ecustom--WarrantsIssuedNewShares_c20220201__20220228__us-gaap--SecuritiesFinancingTransactionAxis__custom--AegisOfferingMember__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_pdd">4,102,200</span></span><span style="background-color: white"> Tradeable Warrants pursuant to the Company’s Public Offering. In March and April 2022, the Company issued <span id="xdx_904_ecustom--WarrantsIssuedNewShares_c20220401__20220422__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_pdd">3,603,604 </span></span><span style="background-color: white">Investor Warrants and <span id="xdx_90F_ecustom--WarrantsIssuedNewShares_c20220401__20220422__us-gaap--SecuritiesFinancingTransactionAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_pdd">9,725,690</span></span><span style="background-color: white"> April Warrants pursuant to two private placements. As of September 30, 2022, <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_zddkFyi2HU22">3,138,507 </span></span><span style="background-color: white">Tradeable Warrants, <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_zhdWxrKMtt5b">2,802,703 </span></span><span style="background-color: white">Investor Warrants, and -<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20220930__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_zJz2X6HrfKe6">0</span></span><span style="background-color: white">- April Warrants were exercised, leaving <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220930__us-gaap--StatementClassOfStockAxis__custom--TradeableWarrantsMember_pdd">963,693 </span></span><span style="background-color: white">Tradeable Warrants, <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220930__us-gaap--StatementClassOfStockAxis__custom--InvestorWarrantsMember_pdd">800,901 </span></span><span style="background-color: white">Investor Warrants and <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220930__us-gaap--StatementClassOfStockAxis__custom--AprilWarrantsMember_z5VvgOMgPGqf">9,725,690 </span></span><span style="background-color: white">April Warrants outstanding. These warrants are dilutive and were included in the diluted earnings per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">In March and April 2022, the Company issued and sold Pre-Funded Warrants to purchase an aggregate of 3,692,276 shares of common stock at a nominal exercise price of $0.001 per share (see Note 3). During the nine months ended September 30, 2022, all of these warrants were exercised and therefore had no remaining dilutive effect.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> 4102200 3603604 9725690 3138507 2802703 0 963693 800901 9725690 <p id="xdx_808_ecustom--ManagementCompensationAndDirectorFeesTextBlock_zEq9aLvX9D3f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><b><span style="text-decoration: underline">Note 9 – <span id="xdx_823_zHID0asKYXn4">Management and Director Compensation</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Company paid its officers cash compensation totaling $<span id="xdx_909_eus-gaap--SalariesWagesAndOfficersCompensation_c20220701__20220930_pp0p0">595,000</span></span><span style="background-color: white"> and $<span id="xdx_90F_eus-gaap--SalariesWagesAndOfficersCompensation_c20210701__20210930_pp0p0">105,000</span></span><span style="background-color: white"> and $<span id="xdx_902_eus-gaap--SalariesWagesAndOfficersCompensation_c20220101__20220930_pp0p0">1,095,000</span></span><span style="background-color: white"> and $<span id="xdx_900_eus-gaap--SalariesWagesAndOfficersCompensation_c20210101__20210930_pp0p0">130,000</span></span><span style="background-color: white"> for the three and nine month periods ended September 30, 2022 and 2021, respectively. Of these amounts attributable to the Company’s CEO, as of September 30, 2021 $<span id="xdx_90B_eus-gaap--SalariesWagesAndOfficersCompensation_pp0p0_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AdvanomicsCorporationMember_zKePttOAwT04">110,000</span></span><span style="background-color: white"> was paid to Advanomics Corporation, a company controlled by the CEO of the Company. In addition, the Company issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210701__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember_z2LcxLfIEhs4">300,000 </span></span><span style="background-color: white">shares of common stock valued at $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pp0p0_c20210701__20210930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersAndDirectorsMember_zlo4RQ3ZwZYc">918,000</span></span><span style="background-color: white"> to its officers during the three months ended September 30, 2021. The value of these shares was based upon the closing price of the Company’s common stock of $3.06 on the issuance date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Company paid its directors cash compensation totaling $<span id="xdx_90B_eus-gaap--NoninterestExpenseDirectorsFees_c20220701__20220930_pp0p0" title="Noninterest Expense Directors Fees"><span id="xdx_901_eus-gaap--NoninterestExpenseDirectorsFees_c20220101__20220930_pp0p0" title="Noninterest Expense Directors Fees">100,000</span></span> and $<span id="xdx_905_eus-gaap--NoninterestExpenseDirectorsFees_c20210701__20210930_pp0p0" title="Noninterest Expense Directors Fees"><span id="xdx_903_eus-gaap--NoninterestExpenseDirectorsFees_c20210101__20210930_pp0p0" title="Noninterest Expense Directors Fees">200,000</span></span> for the three and nine month periods ended September 30, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 595000 105000 1095000 130000 110000 300000 918000 100000 100000 200000 200000 <p id="xdx_801_eus-gaap--SubsequentEventsTextBlock_zdhW2r2PU5dk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><b><span style="text-decoration: underline">Note 10 – <span id="xdx_826_z7sWIC8Hast8">Subsequent Events</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On October 20, 2022, the Company acquired all of the outstanding shares of Nora Pharma Inc., a Canadian generic pharmaceuticals company. The total purchase price of $30,000,000 Canadian (approximately $21,900,000 USD) was paid by paying $20,000,000 Canadian (approximately $14,600,000 USD) in cash, issuing 3,700,000 shares of the Company’s Common Stock valued at $5,000,000 Canadian (approximately $3,650,000 USD), and $5,000,000 Canadian (approximately $3,650,000 USD) which may be paid in the future as an earn-out amount based on target sales. Through the contingent earn-out, the seller, Mr. Malek Chamoun, has the opportunity to earn up to $5,000,000 CAD (approximately $3,650,000 USD) in the form of twenty (20) payments of $250,000 CAD for every $1,000,000 CAD increase in gross sales above Nora Pharma’s June 30, 2022 gross sales, provided that his employment with the Company is not terminated pursuant to the Company’s Employment Agreement with him.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"> </p> The Tradeable Warrants had an initial exercise price of $4.25, subject to adjustment. Upon the closing of the Company’s private placement on March 14, 2022, the exercise price of the Tradeable Warrants was reduced to $2.22, in accordance with the terms thereof. EXCEL 40 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 41 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 42 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 43 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 107 153 1 true 27 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://sunshinebiopharma.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://sunshinebiopharma.com/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://sunshinebiopharma.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://sunshinebiopharma.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statement of Shareholders' Equity (Unaudited) Sheet http://sunshinebiopharma.com/role/StatementOfShareholdersEquity Condensed Consolidated Statement of Shareholders' Equity (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Nature of Business Sheet http://sunshinebiopharma.com/role/NatureOfBusiness Nature of Business Notes 7 false false R8.htm 00000008 - Disclosure - Basis of Presentation Sheet http://sunshinebiopharma.com/role/BasisOfPresentation Basis of Presentation Notes 8 false false R9.htm 00000009 - Disclosure - Impact of Coronavirus (COVID-19) Pandemic Sheet http://sunshinebiopharma.com/role/ImpactOfCoronavirusCovid-19Pandemic Impact of Coronavirus (COVID-19) Pandemic Notes 9 false false R10.htm 00000010 - Disclosure - Reverse Stock Splits Sheet http://sunshinebiopharma.com/role/ReverseStockSplits Reverse Stock Splits Notes 10 false false R11.htm 00000011 - Disclosure - Notes Payable Notes http://sunshinebiopharma.com/role/NotesPayable Notes Payable Notes 11 false false R12.htm 00000012 - Disclosure - Shareholders??? Equity Sheet http://sunshinebiopharma.com/role/ShareholdersEquity Shareholders??? Equity Notes 12 false false R13.htm 00000013 - Disclosure - Warrants Sheet http://sunshinebiopharma.com/role/Warrants Warrants Notes 13 false false R14.htm 00000014 - Disclosure - Net Loss Per Common Share Sheet http://sunshinebiopharma.com/role/NetLossPerCommonShare Net Loss Per Common Share Notes 14 false false R15.htm 00000015 - Disclosure - Management and Director Compensation Sheet http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation Management and Director Compensation Notes 15 false false R16.htm 00000016 - Disclosure - Subsequent Events Sheet http://sunshinebiopharma.com/role/SubsequentEvents Subsequent Events Notes 16 false false R17.htm 00000017 - Disclosure - Warrants (Tables) Sheet http://sunshinebiopharma.com/role/WarrantsTables Warrants (Tables) Tables http://sunshinebiopharma.com/role/Warrants 17 false false R18.htm 00000018 - Disclosure - Nature of Business (Details Narrative) Sheet http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative Nature of Business (Details Narrative) Details http://sunshinebiopharma.com/role/NatureOfBusiness 18 false false R19.htm 00000019 - Disclosure - Reverse Stock Splits (Details Narrative) Sheet http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative Reverse Stock Splits (Details Narrative) Details http://sunshinebiopharma.com/role/ReverseStockSplits 19 false false R20.htm 00000020 - Disclosure - Notes Payable (Details Narrative) Notes http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative Notes Payable (Details Narrative) Details http://sunshinebiopharma.com/role/NotesPayable 20 false false R21.htm 00000021 - Disclosure - Shareholders??? Equity (Details Narrative) Sheet http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative Shareholders??? Equity (Details Narrative) Details http://sunshinebiopharma.com/role/ShareholdersEquity 21 false false R22.htm 00000022 - Disclosure - Warrants (Details) Sheet http://sunshinebiopharma.com/role/WarrantsDetails Warrants (Details) Details http://sunshinebiopharma.com/role/WarrantsTables 22 false false R23.htm 00000023 - Disclosure - Warrants (Details 1) Sheet http://sunshinebiopharma.com/role/WarrantsDetails1 Warrants (Details 1) Details http://sunshinebiopharma.com/role/WarrantsTables 23 false false R24.htm 00000024 - Disclosure - Warrants (Details Narrative) Sheet http://sunshinebiopharma.com/role/WarrantsDetailsNarrative Warrants (Details Narrative) Details http://sunshinebiopharma.com/role/WarrantsTables 24 false false R25.htm 00000025 - Disclosure - Net Loss Per Common Share (Details Narrative) Sheet http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative Net Loss Per Common Share (Details Narrative) Details http://sunshinebiopharma.com/role/NetLossPerCommonShare 25 false false R26.htm 00000026 - Disclosure - Management and Director Compensation (Details Narrative) Sheet http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative Management and Director Compensation (Details Narrative) Details http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation 26 false false All Reports Book All Reports sunshine_i10q-093022.htm sbfm-20220930.xsd sbfm-20220930_cal.xml sbfm-20220930_def.xml sbfm-20220930_lab.xml sbfm-20220930_pre.xml sunshine_ex3101.htm sunshine_ex3102.htm sunshine_ex3201.htm s1.jpg s2.jpg s3.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 45 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "sunshine_i10q-093022.htm": { "axisCustom": 0, "axisStandard": 7, "contextCount": 107, "dts": { "calculationLink": { "local": [ "sbfm-20220930_cal.xml" ] }, "definitionLink": { "local": [ "sbfm-20220930_def.xml" ] }, "inline": { "local": [ "sunshine_i10q-093022.htm" ] }, "labelLink": { "local": [ "sbfm-20220930_lab.xml" ] }, "presentationLink": { "local": [ "sbfm-20220930_pre.xml" ] }, "schema": { "local": [ "sbfm-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 259, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 24, "http://sunshinebiopharma.com/20220930": 7, "http://xbrl.sec.gov/dei/2022": 5, "total": 36 }, "keyCustom": 20, "keyStandard": 133, "memberCustom": 17, "memberStandard": 8, "nsprefix": "SBFM", "nsuri": "http://sunshinebiopharma.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://sunshinebiopharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "SBFM:ReverseStockSplitTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Reverse Stock Splits", "role": "http://sunshinebiopharma.com/role/ReverseStockSplits", "shortName": "Reverse Stock Splits", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "SBFM:ReverseStockSplitTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Notes Payable", "role": "http://sunshinebiopharma.com/role/NotesPayable", "shortName": "Notes Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Shareholders\u2019 Equity", "role": "http://sunshinebiopharma.com/role/ShareholdersEquity", "shortName": "Shareholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "SBFM:WarrantsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Warrants", "role": "http://sunshinebiopharma.com/role/Warrants", "shortName": "Warrants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "SBFM:WarrantsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Net Loss Per Common Share", "role": "http://sunshinebiopharma.com/role/NetLossPerCommonShare", "shortName": "Net Loss Per Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "SBFM:ManagementCompensationAndDirectorFeesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Management and Director Compensation", "role": "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation", "shortName": "Management and Director Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "SBFM:ManagementCompensationAndDirectorFeesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Subsequent Events", "role": "http://sunshinebiopharma.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "SBFM:WarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "SBFM:WarrantsIssuedWithFinancingTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Warrants (Tables)", "role": "http://sunshinebiopharma.com/role/WarrantsTables", "shortName": "Warrants (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "SBFM:WarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "SBFM:WarrantsIssuedWithFinancingTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-02-212022-02-22", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockRedeemedOrCalledDuringPeriodShares", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Nature of Business (Details Narrative)", "role": "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative", "shortName": "Nature of Business (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-02-162022-02-17_custom_AegisOfferingMember", "decimals": "0", "lang": null, "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "span", "p", "SBFM:ReverseStockSplitTextBlock", "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2019-01-312019-02-01_custom_FirstReverseStockSplitMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Reverse Stock Splits (Details Narrative)", "role": "http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative", "shortName": "Reverse Stock Splits (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "SBFM:ReverseStockSplitTextBlock", "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2019-01-312019-02-01_custom_FirstReverseStockSplitMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "role": "http://sunshinebiopharma.com/role/BalanceSheets", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Notes Payable (Details Narrative)", "role": "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative", "shortName": "Notes Payable (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-02-012022-02-17", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Shareholders\u2019 Equity (Details Narrative)", "role": "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative", "shortName": "Shareholders\u2019 Equity (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-02-012022-02-17", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "SBFM:WarrantsIssuedWithFinancingTableTextBlock", "SBFM:WarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-01-012022-09-30_custom_PreFundedWarrantsMember", "decimals": "INF", "first": true, "lang": null, "name": "SBFM:WarrantsIssuedShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Warrants (Details)", "role": "http://sunshinebiopharma.com/role/WarrantsDetails", "shortName": "Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "SBFM:WarrantsIssuedWithFinancingTableTextBlock", "SBFM:WarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-01-012022-09-30_custom_PreFundedWarrantsMember", "decimals": "INF", "first": true, "lang": null, "name": "SBFM:WarrantsIssuedShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "SBFM:WarrantsIssuedWithFinancingTableTextBlock", "SBFM:WarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "AsOf2022-09-30_custom_PreFundedWarrantsMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Warrants (Details 1)", "role": "http://sunshinebiopharma.com/role/WarrantsDetails1", "shortName": "Warrants (Details 1)", "subGroupType": "details", "uniqueAnchor": null }, "R24": { "firstAnchor": { "ancestors": [ "span", "span", "p", "SBFM:WarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-01-012022-09-30_custom_TradeableWarrantsMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Warrants (Details Narrative)", "role": "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative", "shortName": "Warrants (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "SBFM:WarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-01-012022-09-30_custom_TradeableWarrantsMember", "decimals": "0", "lang": null, "name": "us-gaap:ProceedsFromWarrantExercises", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "span", "p", "SBFM:WarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-01-012022-09-30_custom_TradeableWarrantsMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Net Loss Per Common Share (Details Narrative)", "role": "http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative", "shortName": "Net Loss Per Common Share (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-01-012022-09-30_custom_AprilWarrantsMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "span", "p", "SBFM:ManagementCompensationAndDirectorFeesTextBlock", "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-07-012022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SalariesWagesAndOfficersCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Management and Director Compensation (Details Narrative)", "role": "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative", "shortName": "Management and Director Compensation (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "SBFM:ManagementCompensationAndDirectorFeesTextBlock", "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-07-012022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SalariesWagesAndOfficersCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "AsOf2022-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "role": "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "AsOf2022-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-07-012022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "role": "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-07-012022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://sunshinebiopharma.com/role/StatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Condensed Consolidated Statement of Shareholders' Equity (Unaudited)", "role": "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity", "shortName": "Condensed Consolidated Statement of Shareholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - Nature of Business", "role": "http://sunshinebiopharma.com/role/NatureOfBusiness", "shortName": "Nature of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Basis of Presentation", "role": "http://sunshinebiopharma.com/role/BasisOfPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "SBFM:ImpactOfCovid19PandemicTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Impact of Coronavirus (COVID-19) Pandemic", "role": "http://sunshinebiopharma.com/role/ImpactOfCoronavirusCovid-19Pandemic", "shortName": "Impact of Coronavirus (COVID-19) Pandemic", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sunshine_i10q-093022.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "SBFM:ImpactOfCovid19PandemicTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 27, "tag": { "SBFM_AdvanomicsCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Advanomics Corporation [Member]" } } }, "localname": "AdvanomicsCorporationMember", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "SBFM_AegisOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Aegis Offering [Member]" } } }, "localname": "AegisOfferingMember", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative", "http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative" ], "xbrltype": "domainItemType" }, "SBFM_AprilWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "April Warrants [Member]" } } }, "localname": "AprilWarrantsMember", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative", "http://sunshinebiopharma.com/role/WarrantsDetails", "http://sunshinebiopharma.com/role/WarrantsDetails1" ], "xbrltype": "domainItemType" }, "SBFM_CommonStockAndPrefundedWarrantsIssuedInUnderwrittenpublicAndPrivateOfferingsNetOfIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Common stock and pre-funded warrants issued in an underwritten public and private offerings, net of issuance costs" } } }, "localname": "CommonStockAndPrefundedWarrantsIssuedInUnderwrittenpublicAndPrivateOfferingsNetOfIssuanceCosts", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "SBFM_CommonStockAndPrefundedWarrantsIssuedInUnderwrittenpublicAndPrivateOfferingsNetOfIssuanceCostsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:CommonStockAndPrefundedWarrantsIssuedInUnderwrittenpublicAndPrivateOfferingsNetOfIssuanceCostsShares]" } } }, "localname": "CommonStockAndPrefundedWarrantsIssuedInUnderwrittenpublicAndPrivateOfferingsNetOfIssuanceCostsShares", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "SBFM_ConsultingExpense": { "auth_ref": [], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Consulting" } } }, "localname": "ConsultingExpense", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "SBFM_DisclosureImpactOfCoronavirusCovid19PandemicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Impact Of Coronavirus Covid-19 Pandemic" } } }, "localname": "DisclosureImpactOfCoronavirusCovid19PandemicAbstract", "nsuri": "http://sunshinebiopharma.com/20220930", "xbrltype": "stringItemType" }, "SBFM_DisclosureManagementAndDirectorCompensationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Management And Director Compensation" } } }, "localname": "DisclosureManagementAndDirectorCompensationAbstract", "nsuri": "http://sunshinebiopharma.com/20220930", "xbrltype": "stringItemType" }, "SBFM_DisclosureReverseStockSplitsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reverse Stock Splits" } } }, "localname": "DisclosureReverseStockSplitsAbstract", "nsuri": "http://sunshinebiopharma.com/20220930", "xbrltype": "stringItemType" }, "SBFM_DisclosureWarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants" } } }, "localname": "DisclosureWarrantsAbstract", "nsuri": "http://sunshinebiopharma.com/20220930", "xbrltype": "stringItemType" }, "SBFM_FirstReverseStockSplitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "First Reverse Stock Split [Member]" } } }, "localname": "FirstReverseStockSplitMember", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative" ], "xbrltype": "domainItemType" }, "SBFM_ImpactOfCovid19PandemicTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Impact of Coronavirus (COVID-19) Pandemic" } } }, "localname": "ImpactOfCovid19PandemicTextBlock", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/ImpactOfCoronavirusCovid-19Pandemic" ], "xbrltype": "textBlockItemType" }, "SBFM_InvestorWarrants1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investor Warrants 1 [Member]" } } }, "localname": "InvestorWarrants1Member", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative" ], "xbrltype": "domainItemType" }, "SBFM_InvestorWarrants2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investor Warrants 2 [Member]" } } }, "localname": "InvestorWarrants2Member", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative", "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "SBFM_InvestorWarrantsAndAprilWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investor Warrants And April Warrants [Member]" } } }, "localname": "InvestorWarrantsAndAprilWarrantsMember", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "SBFM_InvestorWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investor Warrants [Member]" } } }, "localname": "InvestorWarrantsMember", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative", "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative", "http://sunshinebiopharma.com/role/WarrantsDetails", "http://sunshinebiopharma.com/role/WarrantsDetails1", "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "SBFM_ManagementCompensationAndDirectorFeesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Management and Director Compensation" } } }, "localname": "ManagementCompensationAndDirectorFeesTextBlock", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensation" ], "xbrltype": "textBlockItemType" }, "SBFM_NotePayable20211Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note Payable 20211 [Member]" } } }, "localname": "NotePayable20211Member", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "SBFM_NotePayable20212Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note Payable 20212 [Member]" } } }, "localname": "NotePayable20212Member", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "SBFM_NotePayable20213Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note Payable 20213 [Member]" } } }, "localname": "NotePayable20213Member", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "SBFM_OfficeExpense": { "auth_ref": [], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 5.0, "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Office" } } }, "localname": "OfficeExpense", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "SBFM_OfficerAndDirectorRemuneration": { "auth_ref": [], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 6.0, "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Officer and director remuneration" } } }, "localname": "OfficerAndDirectorRemuneration", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "SBFM_OfficersAndDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Officers And Directors [Member]" } } }, "localname": "OfficersAndDirectorsMember", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "SBFM_PatentingFees": { "auth_ref": [], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 7.0, "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Patent fees" } } }, "localname": "PatentingFees", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "SBFM_PreFundedWarrants1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Pre Funded Warrants 1 [Member]" } } }, "localname": "PreFundedWarrants1Member", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative", "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "SBFM_PreFundedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Pre Funded Warrants [Member]" } } }, "localname": "PreFundedWarrantsMember", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative", "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative", "http://sunshinebiopharma.com/role/WarrantsDetails", "http://sunshinebiopharma.com/role/WarrantsDetails1" ], "xbrltype": "domainItemType" }, "SBFM_PreferredStockPurchasedFromRelatedPartyShares": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Preferred stock purchased from related party, shares" } } }, "localname": "PreferredStockPurchasedFromRelatedPartyShares", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "SBFM_PreferredStockPurchasedFromRelatedPartyValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "PreferredStockPurchasedFromRelatedPartyValue", "negatedLabel": "Preferred stock purchased from related party" } } }, "localname": "PreferredStockPurchasedFromRelatedPartyValue", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "SBFM_ProceedsPublicOfferingNet": { "auth_ref": [], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "ProceedsPublicOfferingNet", "negatedLabel": "Proceeds public offerings, net" } } }, "localname": "ProceedsPublicOfferingNet", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "SBFM_RedemptionOrProceedsFromPreferredShares": { "auth_ref": [], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Purchase of preferred shares" } } }, "localname": "RedemptionOrProceedsFromPreferredShares", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "SBFM_ReverseStockSplitTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ReverseStockSplitTextBlock", "verboseLabel": "Reverse Stock Splits" } } }, "localname": "ReverseStockSplitTextBlock", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/ReverseStockSplits" ], "xbrltype": "textBlockItemType" }, "SBFM_SecondReverseStockSplitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Second Reverse Stock Split [Member]" } } }, "localname": "SecondReverseStockSplitMember", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative" ], "xbrltype": "domainItemType" }, "SBFM_StockIssuedForNoteConversionsIncludingInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Stock issued for note conversions including interest" } } }, "localname": "StockIssuedForNoteConversionsIncludingInterest", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "SBFM_StockIssuedForPaymentInterestOnNotesPayable": { "auth_ref": [], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Stock issued for payment interest" } } }, "localname": "StockIssuedForPaymentInterestOnNotesPayable", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "SBFM_ThirdReverseStockSplitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Third Reverse Stock Split [Member]" } } }, "localname": "ThirdReverseStockSplitMember", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative" ], "xbrltype": "domainItemType" }, "SBFM_TradeableWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Tradeable Warrants [Member]" } } }, "localname": "TradeableWarrantsMember", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative", "http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative", "http://sunshinebiopharma.com/role/WarrantsDetails", "http://sunshinebiopharma.com/role/WarrantsDetails1", "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "SBFM_WarrantExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Expiration Date" } } }, "localname": "WarrantExpirationDate", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/WarrantsDetails", "http://sunshinebiopharma.com/role/WarrantsDetails1" ], "xbrltype": "stringItemType" }, "SBFM_WarrantsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WarrantsDisclosureTextBlock", "verboseLabel": "Warrants" } } }, "localname": "WarrantsDisclosureTextBlock", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/Warrants" ], "xbrltype": "textBlockItemType" }, "SBFM_WarrantsIssuedNewShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants issued new, shares", "verboseLabel": "[custom:WarrantsIssuedNewShares]" } } }, "localname": "WarrantsIssuedNewShares", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative", "http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative", "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "SBFM_WarrantsIssuedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of shares" } } }, "localname": "WarrantsIssuedShares", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/WarrantsDetails" ], "xbrltype": "sharesItemType" }, "SBFM_WarrantsIssuedWithFinancingTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants issued with financing" } } }, "localname": "WarrantsIssuedWithFinancingTableTextBlock", "nsuri": "http://sunshinebiopharma.com/20220930", "presentation": [ "http://sunshinebiopharma.com/role/WarrantsTables" ], "xbrltype": "textBlockItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r364", "r366", "r367" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r24", "r302" ], "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r129", "r130" ], "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r16", "r37", "r38", "r39", "r335", "r348", "r349" ], "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated comprehensive (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r14", "r302" ], "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Capital paid in excess of par value" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r79", "r80", "r81", "r252", "r253", "r254", "r274" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r255" ], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising and Marketing" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r9", "r75", "r115", "r118", "r124", "r132", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r263", "r267", "r278", "r300", "r302", "r320", "r333" ], "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r23", "r75", "r132", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r263", "r267", "r278", "r300", "r302" ], "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative", "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r2", "r78", "r110" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r8", "r68" ], "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r62", "r68", "r70" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and Cash Equivalents at End of Period", "periodStartLabel": "Cash and Cash Equivalents at Beginning of Period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r62", "r283" ], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r11", "r12", "r13", "r72", "r75", "r93", "r94", "r95", "r97", "r99", "r107", "r108", "r109", "r132", "r139", "r143", "r144", "r145", "r148", "r149", "r190", "r191", "r195", "r199", "r206", "r278", "r369" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical", "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative", "http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative", "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative", "http://sunshinebiopharma.com/role/WarrantsDetails", "http://sunshinebiopharma.com/role/WarrantsDetails1", "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "verboseLabel": "Warrants exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative", "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative", "http://sunshinebiopharma.com/role/WarrantsDetails", "http://sunshinebiopharma.com/role/WarrantsDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative", "http://sunshinebiopharma.com/role/WarrantsDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r79", "r80", "r274" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover", "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative", "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative", "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r13", "r206" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r13", "r302" ], "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, $0.001 par value per share; 3,000,000,000 shares authorized; 18,885,632 and 2,591,240 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income [Member]" } } }, "localname": "ComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r41", "r43", "r44", "r51", "r325", "r341" ], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Net (loss)", "totalLabel": "Comprehensive (Loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity", "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r54", "r75", "r132", "r139", "r140", "r141", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r278" ], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of sales" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r71", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r168", "r175", "r176", "r178", "r185" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Notes Payable" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/NotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r151", "r179", "r180", "r292", "r294", "r295" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Face Value" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r28", "r171", "r292" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Interest Rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r29", "r154", "r277" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Maturity Date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r30", "r74", "r77", "r151", "r152", "r153", "r154", "r155", "r156", "r158", "r164", "r165", "r166", "r167", "r169", "r170", "r171", "r172", "r173", "r174", "r177", "r179", "r180", "r181", "r182", "r207", "r211", "r212", "r213", "r291", "r292", "r294", "r295", "r332" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DepositsAssetsCurrent": { "auth_ref": [ "r22" ], "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.", "label": "Deposits" } } }, "localname": "DepositsAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r66", "r136" ], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 9.0, "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r66", "r136" ], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r214", "r331" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "Dividends" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r52", "r84", "r85", "r86", "r87", "r88", "r92", "r93", "r97", "r98", "r99", "r103", "r104", "r275", "r276", "r326", "r342" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic (loss) per common share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]" } } }, "localname": "EarningsPerShareBasicLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r100", "r101", "r102", "r105" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Net Loss Per Common Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/NetLossPerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r283" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r283" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Foreign currency translation adjustment" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r45", "r46", "r47", "r79", "r80", "r81", "r83", "r89", "r91", "r106", "r133", "r206", "r214", "r252", "r253", "r254", "r258", "r259", "r274", "r284", "r285", "r286", "r287", "r288", "r289", "r296", "r344", "r345", "r346" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover", "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r279", "r280", "r281", "r282" ], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign exchange gain" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r66", "r183", "r184" ], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Debt forgiveness", "negatedLabel": "Debt forgiveness" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows", "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r56" ], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "totalLabel": "Total General and Administrative Expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "General and Administrative Expenses:" } } }, "localname": "GeneralAndAdministrativeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r53", "r75", "r115", "r117", "r120", "r123", "r125", "r132", "r139", "r140", "r141", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r278" ], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r76", "r90", "r91", "r114", "r257", "r260", "r261", "r343" ], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r69" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r65" ], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (decrease) in Accounts Payable & accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r65" ], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Decrease in accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "auth_ref": [ "r65" ], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.", "label": "Increase (decrease) in interest payable" } } }, "localname": "IncreaseDecreaseInInterestPayableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r65" ], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "(Increase) in inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r65" ], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "(Increase) decrease in prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InducedConversionOfConvertibleDebtExpense": { "auth_ref": [ "r150" ], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.", "label": "Loss on debt conversion", "negatedLabel": "Loss on debt conversions" } } }, "localname": "InducedConversionOfConvertibleDebtExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows", "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r48", "r113", "r290", "r293", "r328" ], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeDebtSecuritiesOperating": { "auth_ref": [], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income, amortization of premium and accretion of discount, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading); classified as operating.", "label": "Interest income" } } }, "localname": "InterestIncomeDebtSecuritiesOperating", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r69" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r60", "r63", "r69" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r26" ], "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest payable" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r323", "r339" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Interest Payable" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r4", "r20", "r302" ], "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r66" ], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Stock issued for services" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LegalFees": { "auth_ref": [ "r55" ], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 4.0, "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.", "label": "Legal" } } }, "localname": "LegalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r25", "r75", "r119", "r132", "r139", "r140", "r141", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r264", "r267", "r268", "r278", "r300", "r301" ], "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND SHAREHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r19", "r75", "r132", "r278", "r302", "r322", "r337" ], "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r7", "r27", "r75", "r132", "r139", "r140", "r141", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r264", "r267", "r268", "r278", "r300", "r301", "r302" ], "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r30" ], "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Long-term portion of notes payable" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r30", "r138" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r62" ], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash Flows Provided by Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows From Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r62", "r64", "r67" ], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash Flows (Used) in Operations" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows From Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r40", "r42", "r47", "r50", "r67", "r75", "r82", "r84", "r85", "r86", "r87", "r90", "r91", "r96", "r115", "r117", "r120", "r123", "r125", "r132", "r139", "r140", "r141", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r276", "r278", "r324", "r340" ], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net (Loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoninterestExpenseDirectorsFees": { "auth_ref": [ "r327" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noninterest expense related to directors' fees which are fees paid by an Entity to its directors. Directors' fees may be paid in addition to salary and other benefits.", "label": "Noninterest Expense Directors Fees" } } }, "localname": "NoninterestExpenseDirectorsFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r57" ], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total Other Income (Expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income (Expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r10", "r321", "r334" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable [Default Label]", "verboseLabel": "Notes Payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OffsettingAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Offsetting Assets [Line Items]" } } }, "localname": "OffsettingAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingAssetsTable": { "auth_ref": [ "r33", "r34" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements.", "label": "Offsetting Assets [Table]" } } }, "localname": "OffsettingAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r115", "r117", "r120", "r123", "r125" ], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "(Loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r2", "r271" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Nature of Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/NatureOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": { "auth_ref": [ "r36", "r37" ], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "(Loss) from foreign exchange translation" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r12", "r190" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockRedemptionPricePerShare": { "auth_ref": [ "r189", "r207", "r209" ], "lang": { "en-us": { "role": { "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.", "label": "Redemption price" } } }, "localname": "PreferredStockRedemptionPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r12", "r190" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r12", "r302" ], "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Series B $0.10 par value per share; 1,000,000 shares authorized; 10,000 and 1,000,000 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r5", "r21", "r134", "r135" ], "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative", "http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative", "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r58" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r58" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds from Issuance of Private Placement", "verboseLabel": "Proceeds from Issuance of private placement" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative", "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r58" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative", "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r58" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from Warrant Exercises" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r350", "r351" ], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Accounting" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r40", "r42", "r47", "r61", "r75", "r82", "r90", "r91", "r115", "r117", "r120", "r123", "r125", "r132", "r139", "r140", "r141", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r262", "r265", "r266", "r269", "r270", "r276", "r278", "r329" ], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net (Loss)", "totalLabel": "Net (loss) before income taxes" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows", "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r137", "r302", "r330", "r338" ], "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r218", "r297", "r298" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r218", "r297", "r299", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r59" ], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of notes payable", "negatedLabel": "Payments of notes payable" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative", "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r256", "r306", "r352" ], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 8.0, "parentTag": "us-gaap_GeneralAndAdministrativeExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "R&D" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r15", "r214", "r302", "r336", "r347", "r349" ], "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated (deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r79", "r80", "r81", "r83", "r89", "r91", "r133", "r252", "r253", "r254", "r258", "r259", "r274", "r344", "r346" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r49", "r75", "r111", "r112", "r116", "r121", "r122", "r126", "r127", "r128", "r132", "r139", "r140", "r141", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r278", "r329" ], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalariesWagesAndOfficersCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salary and Wage, Excluding Cost of Good and Service Sold" } } }, "localname": "SalariesWagesAndOfficersCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r219", "r220", "r221", "r222", "r223" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "auth_ref": [ "r93", "r94", "r97", "r99", "r104" ], "lang": { "en-us": { "role": { "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.", "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]" } } }, "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r11", "r12", "r13", "r72", "r107", "r108", "r186", "r187", "r188", "r190", "r191", "r192", "r193", "r195", "r199", "r204", "r206", "r207", "r208", "r210", "r211", "r212", "r213", "r214" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r216", "r224" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of outstanding warrants" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/WarrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuritiesFinancingTransactionAxis": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Information by type of securities financing transactions, including, but not limited to those measured at fair value or cost.", "label": "Securities Financing Transaction [Axis]" } } }, "localname": "SecuritiesFinancingTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative", "http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative", "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SecuritiesFinancingTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Securities Financing Transaction [Line Items]" } } }, "localname": "SecuritiesFinancingTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SecuritiesFinancingTransactionTable": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Schedule, as of the balance sheet date, of security financing transactions by type, the aggregate value of securities financing transactions by type and aggregate acquisition price by type of security financing transaction.", "label": "Securities Financing Transaction [Table]" } } }, "localname": "SecuritiesFinancingTransactionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SecuritiesFinancingTransactionTypeDomain": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Measurement of financing transaction securities held." } } }, "localname": "SecuritiesFinancingTransactionTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative", "http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative", "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [ "r11", "r12", "r206" ], "lang": { "en-us": { "role": { "documentation": "Series B preferred stock.", "label": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical", "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative", "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative", "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending Balance shares", "periodStartLabel": "Beginnig Balance shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r11", "r12", "r13", "r72", "r75", "r93", "r94", "r95", "r97", "r99", "r107", "r108", "r109", "r132", "r139", "r143", "r144", "r145", "r148", "r149", "r190", "r191", "r195", "r199", "r206", "r278", "r369" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical", "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative", "http://sunshinebiopharma.com/role/NetLossPerCommonShareDetailsNarrative", "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative", "http://sunshinebiopharma.com/role/WarrantsDetails", "http://sunshinebiopharma.com/role/WarrantsDetails1", "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r32", "r45", "r46", "r47", "r79", "r80", "r81", "r83", "r89", "r91", "r106", "r133", "r206", "r214", "r252", "r253", "r254", "r258", "r259", "r274", "r284", "r285", "r286", "r287", "r288", "r289", "r296", "r344", "r345", "r346" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover", "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical", "http://sunshinebiopharma.com/role/Cover", "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity", "http://sunshinebiopharma.com/role/WarrantsDetails", "http://sunshinebiopharma.com/role/WarrantsDetails1", "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r79", "r80", "r81", "r106", "r307" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheetsParenthetical", "http://sunshinebiopharma.com/role/Cover", "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity", "http://sunshinebiopharma.com/role/WarrantsDetails", "http://sunshinebiopharma.com/role/WarrantsDetails1", "http://sunshinebiopharma.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r31", "r169", "r206", "r207", "r214" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Exercise of warrants, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Common stock issued for services shares", "verboseLabel": "Stock Issued During Period, Shares, Issued for Services" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative", "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r12", "r13", "r206", "r214" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative", "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Common stock issued for the reduction of note payable and payment of interest shares" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r32", "r206", "r214" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Exercise of warrants" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Common stock issued for services", "verboseLabel": "Stock Issued During Period, Value, Issued for Services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/ManagementAndDirectorCompensationDetailsNarrative", "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Common stock issued for the reduction of note payable and payment of interest" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRedeemedOrCalledDuringPeriodShares": { "auth_ref": [ "r206" ], "lang": { "en-us": { "role": { "documentation": "Number of stock bought back by the entity at the exercise price or redemption price.", "label": "Stock Redeemed or Called During Period, Shares", "verboseLabel": "Redeemed shares" } } }, "localname": "StockRedeemedOrCalledDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative", "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r13", "r17", "r18", "r75", "r131", "r132", "r278", "r302" ], "calculation": { "http://sunshinebiopharma.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "TOTAL SHAREHOLDERS' EQUITY" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets", "http://sunshinebiopharma.com/role/StatementOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SHAREHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r73", "r191", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r205", "r214", "r217", "r273" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Shareholders\u2019 Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/ShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Stockholders' Equity, Reverse Stock Split" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r303", "r304" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplementary Disclosure of Cash Flow Information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TransactionDomain": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Agreement between buyer and seller for the exchange of financial instruments." } } }, "localname": "TransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TransactionTypeAxis": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.", "label": "Transaction Type [Axis]" } } }, "localname": "TransactionTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/ReverseStockSplitsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax": { "auth_ref": [ "r272" ], "calculation": { "http://sunshinebiopharma.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.", "label": "Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax", "negatedLabel": "Foreign exchange (gain) loss" } } }, "localname": "UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/Cover", "http://sunshinebiopharma.com/role/NatureOfBusinessDetailsNarrative", "http://sunshinebiopharma.com/role/ShareholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r92", "r99" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Common Shares Outstanding (Basic)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://sunshinebiopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r105": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "40", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123467568&loc=d3e6835-112609" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629" }, "r185": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21564-112644" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r217": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r271": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r304": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.14)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r353": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r354": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r355": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r356": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r357": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r358": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r359": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r360": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r361": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r362": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r363": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r364": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r365": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r366": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r367": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r368": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r369": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r370": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r371": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r372": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r373": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r78": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" } }, "version": "2.1" } ZIP 46 0001683168-22-007290-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-22-007290-xbrl.zip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µ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�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